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I. Abstract 
 
Recently, we showed that the E3 ubiquitin ligase Parkin, which is associated with Parkinson’s 
Disease (PD), influences NF-κB signaling via increased activation of the linear ubiquitin 
assembly complex (LUBAC). Huntington’s Disease (HD) shares pathologic features such as 
mitochondrial alterations and augmented neuronal cell death with PD. Therefore, we were 
interested in the question if similar signaling pathways might be affected in HD and PD. To 
address this issue, we examined whether and how Huntingtin aggregates might alter the pro-
survival NF-κB pathway. 
Using HD cell culture models we discovered that Huntingtin aggregates sequester and trap 
components of the LUBAC, thereby blocking one of the first steps of the TNF-α-induced NF-
κB pathway. As a consequence, nuclear translocation of the transcription factor NF-κB is 
decreased leading to reduced expression of NF-κB responsive target genes. OPA1, a key 
regulator of mitochondrial fusion, belongs to the group of NF-κB responsive target genes, 
which can explain why increased mitochondrial fragmentation is found in HD. Due to the 
impairment of the pro-survival NF-κB pathway, two other TNF-α-induced pro-apoptotic 
pathways that are usually suppressed by a subset of NF-κB targets, are up-regulated in cells 
with Huntingtin aggregates: the JNK signaling pathway and the caspase cascade. This switch 
from pro-survival NF-κB signaling to programmed cell death caused by an expansion of the 
polyQ stretch in Huntingtin can explain the increased vulnerability to stress-induced cell 
death. Interestingly, overexpression of Parkin as well as HOIP, which is the catalytic subunit 
of the LUBAC, can restore defective NF-κB signaling and thereby rescue from mitochondrial 
fragmentation and increased JNK activation induced by polyQ aggregates. Moreover, 
knockdown of the two proteins Parkin or HOIP results in increased toxicity of Huntingtin 
aggregates.  
Having demonstrated that the NF-κB pathway is not only affected in PD, but also in HD, it is 
tempting to speculate that also other neurodegenerative diseases might share an impairment in 
this common pathway. 
 
II. Zusammenfassung 
 
Vor kurzem konnten wir zeigen, dass die E3 Ubiquitin-Ligase Parkin, die mit der Parkinson-
Krankheit (Parkinson’s Disease, PD) in Verbindung steht, den NF-κB-Signalweg durch eine 
erhöhte Aktivierung des linearen Ubiquitin-Assemblierungskomplexes (Linear Ubiquitin 
Assembly Complex, LUBAC) beeinflusst. Die Huntington-Krankheit (Huntington’s Disease, 
HD) weist gemeinsame pathologische Eigenschaften wie mitochondriale Veränderungen und 
vermehrten neuronalen Zelltod mit der Parkinson-Krankheit auf. Deshalb waren wir an der 
Frage interessiert, ob ähnliche Signalwege bei HD und PD betroffen sind. Um diese 
Hypothese zu addressieren, untersuchten wir, ob und wie Huntingtin-Aggregate den 
überlebensfördernden NF-κB-Signalweg beeinflussen können. 
Wir entdeckten mittels HD Zellkulturmodellen, dass Huntingtin-Aggregate Komponenten des 
LUBAC binden und abfangen, wodurch sie einen der ersten Schritte des TNF-α-induzierten 
NF-κB-Wegs blockieren. Folglich tritt eine verminderte nukleäre Translokation des 
Transkriptionsfaktors NF-κB auf, die zu reduzierter Expression von NF-κB-responsiven 
Zielgenen führt. OPA1, ein wichtiger Regulator von mitochondrialer Fusion, gehört zur 
Gruppe der NF-κB-responsiven Zielgene, was die erhöhte mitochondriale Fragmentierung bei 
HD erklären kann. Wegen der Beeinträchtigung des überlebensfördernden NF-κB-Signalwegs 
sind zwei andere TNF-α-induzierte apoptosefördernde Signalwege, die normalerweise durch 
einen kleinen Teil der NF-κB Zielgene unterdrückt werden, in Zellen mit Huntingtin-
Aggregaten hochreguliert: der JNK-Signalweg und die Caspase-Kaskade. 
Dieses Umschalten von überlebensfördernder NF-κB Wirkung hin zu programmiertem 
Zelltod aufgrund des expandierten polyQ-Strangs in Huntingtin kann die gesteigerte Stress-
induzierte Zelltod-Rate erklären. Interessanterweise kann Überexpression von Parkin oder 
HOIP, der katalytischen Untereinheit des LUBAC, eine gestörte NF-κB-Aktivierung 
wiederherstellen und dadurch vor mitochondrialer Fragmentierung und erhöhter JNK-
Aktivierung schützen, die durch polyQ-Aggregate induziert werden. Zudem führt eine 
verminderte Expression von Parkin oder HOIP zu einer erhöhten Toxizität der Huntingtin-
Aggregate. 
Nachdem gezeigt wurde, dass der NF-κB Signalweg nicht nur bei PD, sondern auch bei HD 
betroffen ist, könnte man mutmaßen, dass sogar noch weitere neurodegenerative 
Erkrankungen eine Beeinträchtung dieses Stoffwechselwegs gemeinsam haben könnten. 
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1. Introduction 
1.1 Parkin 
1.1.1 Parkinson’s Disease 
a) History 
Parkinson’s Disease (PD) is the most common movement disorder and after Alzheimer’s 
Disease the second most common neurodegenerative disease [Winklhofer and Haass, 2010]. 
It is estimated that PD affects four to six million people worldwide and 1.2 million people in 
Europe [http://www.epda.eu.com]. The disease was first documented by the English physician 
James Parkinson, who described the symptomes of idiopathic PD in his famous “Essay on the 
Shaking Palsy” in 1817. Another notable contribution to the understanding of the disease was 
made by the French neurologist Jean-Martin Charcot with his studies differentiating between 
rigidity, weakness and bradykinesia. He also pleaded for renaming the disease in honor of 
James Parkinson [Lees 2007]. In 1912, Friedrich Heinrich (Frederic) Lewy discovered 
microscopic particles in affected PD brains, which were later named “Lewy bodies” [Holdorff 
2002]. It took almost a whole century, until α-Synuclein was identified as the main 
component of the Lewy bodies in 1997 [Spillantini 1997, Schulz-Schaeffer 2010]. 
 
    
Fig. 1: (left) James Parkinson (1755 - 1824) and (right) Frederic Lewy (1885 - 1950). 
[http://www.biography.com/people/james-parkinson-21226395; http://lewybody.org/science] 
 
b) Etiology 
So far, little is known about the etiology of Parkinson’s Disease. A number of environmental 
factors have been associated with an increased risk of sporadic PD including insecticides, 
pesticides, such as rotenone or paraquat, and herbicides, such as Agent Orange [de Lau and 
Breteler 2006]. Besides that, the most important risk factor for the development and 
progression of PD seems to be aging. With increasing age, the prevalence of PD increases as 
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well and this age-specific prevalence is remarkably similar in the majority of countries in 
Europe [Hindle 2010]. The mean age of onset is typically around 60 years, although in 5 to 
10% of cases, classified as young onset, patients are affected between the age of 20 and 50 
[Samii 2004]. The process of aging is thought to be a stochastic combination of predictable 
and random effects that lead to the accumulation of unrepaired cellular damage, weakened 
cellular repair and compensatory mechanisms. Aging is associated with mitochondrial 
dysfunction, increased free radical production and oxidative stress, which may lead to 
genomic instability and DNA mutations, with shortening of telomeres promoting reduced 
survival [Kirkwood 2003, Migliore and Coppedè 2009]. Another characteristic feature is the 
age-related decline in proteasomal activity leading to a lack in the degradation of damaged or 
ubiquitinated proteins and an increase in abnormal deposition of cellular brain proteins [Tai 
and Schuman 2008]. All of these age-related changes are relevant to the etiology and 
pathogenesis of PD, although it is not clear yet, if PD reflects a failure of the normal cellular 
compensatory mechanisms in vulnerable brain regions, and if this vulnerability is increased 
by aging [Hindle 2010].  
Furthermore, several genetic mutations could be identified, which are responsible for 
monogenic familial PD forms (up to 10% of all PD cases). Genetic studies revealed mutations 
in 13 genes, which are mostly associated with rare forms of PD with early onset. However, 
only six of these genes have conclusively been linked to PD so far (Table 1).  
 
gene gene product inheritance putative function 
PARK1/4 α-Synuclein (SNCA) AD 
vesicle trafficking/  
synaptic plasticity 
PARK2 Parkin AR E3 ubiquitin ligase 
PARK6 PINK1 AR mitochondrial kinase 
PARK7 DJ-1 AR cytosolic redox-sensitive protein 
PARK8 LRRK2 AD MAPKK kinase 
PARK9 ATP13A2 AR lysosomal ATPase 
 
Table 1: Only genes with compelling evidence for association with PD are listed. 
AD = autosomal dominant, AR = autosomal recessive 
 
c) Genetics 
Through the identification of genes responsible for the rare familial forms of PD, our 
understanding of the molecular mechanisms underlying the pathogenesis of PD was 
tremendously improved.  
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PARK1/PARK4 (α-Synuclein) 
In 1997, the first discovered risk gene for familial PD was PARK1/PARK4 [Polymeropoulos 
1997]. The corresponding protein is localized in the cytoplasm of neurons, where it is closely 
associated with synaptic vesicles [Maroteaux 1988]. As mentioned in the previous chapter, α-
Synuclein is a major component of Lewy bodies, which provides an interesting link between 
sporadic and familial PD. Pathogenic mutations in this protein lead to increased self-assembly 
and fibrillization [Greenbaum 2005]. Moreover, genomic multiplication of the α-Synuclein 
locus enhances insoluble α-Synuclein aggregation. An ongoing debate discusses which 
species of the protein implicates the highest toxicity for the cell - oligomers, protofibrils or 
fibrils.  
 
PARK2 (Parkin) 
Parkin was the first recessive gene which was found to be connected to PD. Mutations in this 
E3 ubiquitin ligase were described in 1998 by Kitada and co-workers, who identified it as the 
cause of recessive PD with juvenile onset in a Japanese family [Kitada 1998]. Mutations in 
PARK2 account for the majority of autosomal recessive Parkinsonism. Interestingly, patients 
with Parkin mutations tend to develop symptoms at a much younger age, such as below 30 
years [Mata 2004]. A more detailed description of Parkin will be given in chapter 1.1.2.  
 
PARK6 (PINK1) 
PTEN-induced putative kinase 1 (PINK1) is a ubiquitously expressed protein, which is highly 
conserved between species. It contains an N-terminal mitochondrial targeting sequence, a 
transmembrane domain and a C-terminal serine-threonine kinase domain. Mutations in the 
PINK1 gene are the second most common cause of autosomal recessive Parkinsonism. 
Pathogenic PINK1 mutations cluster in the kinase domain leading to an effect on either kinase 
activity or protein stability supporting a loss-of-function mechanism. 
In contrast to Drosophila PINK1 mutants showing reduced life span, male sterility and 
apoptotic flight muscle degeneration, PINK1 knockout (KO) mice do not display an overt 
phenotype. Impaired mitochondrial respiration in the striatum of PINK1 KO mice and 
decreased complex I activity were observed in PINK1-deficient mice and flies pointing to a 
bioenergetic deficit when PINK1 is missing [Pilsl and Winklhofer 2011]. 
First evidence for a genetic interaction of PINK1 and Parkin came from studies in fruit flies, 
which indicated that Parkin-deficient flies show a similar phenotype as PINK1-deficient flies. 
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Importantly, the PINK1 mutant phenotype could be restored by overexpression of Parkin, but 
not vice versa. These observations suggest a function of PINK1 and Parkin in the same 
pathway with Parkin acting dowstream of PINK1.  
 
 
 
Fig. 2: Concept of mitophagy. Mitochondrial depolarization leads to stabilization of PINK1 on the surface of 
mitochondria. PINK1 then recruits and activates Parkin, which in turn fosters ubiquitination and remodeling of 
the outer mitochondrial membrane to attract the autophagic machinery. These damaged mitochondria become 
engulfed by autophagosomes fusing with lysosomes resulting in formation of autophagolysosomes [Winklhofer 
2014]. 
 
Additional evidence for such a linear pathway was provided by cell-culture studies 
demonstrating that Parkin promotes autophagic degradation of depolarized mitochondria in a 
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PINK1-dependent manner. When HeLa cells overexpressing Parkin are treated with carbonyl 
cyanide 3-chlorophenylhydrazone (CCCP) or carbonyl cyanide 4-trifluoromethoxy-
phenylhydrazone (FCCP), mitochondrial depolarization leads to stabilization of PINK1 at the 
outer mitochondrial membrane. Then, PINK1 recruits and activates Parkin at the outer 
mitochondrial membrane resulting in Parkin-dependent ubiquitination and remodeling of the 
outer mitochondrial membrane, which attracts the autophagic machinery. Next, 
autophagosomes engulf damaged mitochondria and finally fuse with lysosomes to form 
autophagolysosomes. This process is termed mitophagy (Fig. 2). At present, it is a great 
challenge to transfer this artificial setting with harsh treatment of cells to more physiological 
conditions in order to examine the relevance of the mitophagy concept to the observed 
phenotypes from PINK1- or Parkin-deficient animal models and, what is even more 
important, to pathogenic mechanisms in patients [Winklhofer 2014]. 
 
PARK7 (DJ-1) 
In 2003, Bonifati et al. discovered a large deletion and missense mutation in the DJ-1 gene in 
Italian and Dutch PD patients, leading to the identification of the DJ-1 gene as a causative 
gene for familial PD with recessive inheritance [Bonifati 2003]. Compared to Parkin and 
PINK1, the number of mutations in the DJ-1 gene is relatively small. Diverse functions 
including transcriptional regulation, antioxidative stress reaction as well as chaperone, 
protease, and mitochondrial regulation have been described for DJ-1. Its activity is regulated 
by the oxidative status, especially that of cysteine 106 [Ariga 2013]. 
 
PARK8 (LRKK2) 
Discovered in 2004, Leucine-rich repeat kinase 2 (LRRK2)/Dardarin encodes a protein 
consisting of multiple domains: an N-terminal ankyrin domain, a leucin-rich repeat, a 
GTPase/ROC (ras of complex proteins) domain, a COR (C-terminal of ROC domain) a kinase 
and a WD40 domain [Taylor 2006]. In 2008, LRKK2 was also linked to Crohn’s disease by 
genome-wide association studies (GWAS) [Barrett 2008]. 
Among the six clearly PD-associated gene loci, only α-Synuclein and LRRK2 mutations 
cause autosomal dominant forms of the disease. So far, LRRK2 has been found to be the most 
frequent cause of late-onset PD. The mutations are found in 5-6 % of patients with familial 
PD and have also been implicated in sporadic PD [Ho 2014]. 
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Currently, LRRK2 is considered to be a potential therapeutic target for the treatment of PD. 
Several pathogenic mutations were found and the majority of them is located in the dual 
catalytic domains of LRRK2. The most common mutation G2019S results in increased kinase 
activity of LRRK2 and therefore, much effort is put into the development of potent and 
specific inhibitors of LRRK2 kinase activity [Dzamko 2013].  
 
PARK9 (ATP13A2) 
Mutations in the ATP13A2 (PARK9) gene lead to the Kufor-Rakeb syndrome (KRS), a 
severe early-onset autosomal recessive form of PD with dementia [Ramirez 2006]. ATP13A2 
is a lysosomal transmembrane protein belonging to the P5-type ATPase family and seems to 
be a critical regulator of lysosomal functions. As overexpression of ATP13A2 suppresses α-
Synuclein toxicity, two genetic risk factors of PD are connected, highlighting the central role 
of ATP13A2 in PD. Loss of ATP13A2 function was also linked to neuronal ceroid 
lipofuscinosis (NCL), a lysosomal storage disorder, implicating an impairment of the 
lysosomal pathway in KRS and PD [van Veen 2014]. 
 
d) Symptoms 
The primary symptoms of Parkinson's Disease are all related to voluntary and involuntary 
motor function. Moreover, they usually start on one side of the body. Being mild at first, the 
symptoms will progress over time. Studies have shown that by the time when primary 
symptoms appear, individuals with PD have already lost 60 to 80% of the dopaminergic 
neurons.  The four primary motor symptoms include tremor, rigidity, bradykinesia or 
hypokinesia and postural instability (Fig. 3), while additional non-motor symptoms like sleep 
abnormalities, depression and cognitive impairment occur [Lang and Lonzano 1998, Pilsl and 
Winklhofer 2011]. 
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Fig. 3: Primary motor symptoms of Parkinson’s Disease: 
Tremor (involuntary, rhythmic shaking of a limb, head, or 
entire body) – The most recognised symptom of Parkinson's 
Disease, tremor often starts with an occasional tremor in one 
finger that eventually spreads to the whole arm. The tremor 
may affect only one part or side of the body, especially in the 
early stages of the disease. Not everyone with Parkinson's 
Disease has tremor. 
Rigidity (stiffness or inflexibility of the limbs or joints) – The 
muscle rigidity experienced with Parkinson's Disease often 
begins in the legs and neck. Rigidity affects most people. The 
muscles become tense and contracted, and some people may 
feel pain or stiffness. 
Bradykinesia or akinesia (slowness of movement or absence 
of movement) – Bradykinesia is one of the classic symptoms of 
Parkinson's Disease. After a number of years, people suffering 
from PD may experience akinesia, or "freezing," and not be 
able to move at all. 
Postural Instability (impaired balance and coordination) – A 
person with postural instability may have a stooped position, 
with head bowed and shoulders drooped.  
 
[https://bootheels33.wordpress.com/2013/04/03/when-p-was-for-parkinsons-disease; 
http://www.medtronic.co.uk/your-health/parkinsons-disease] 
 
e) Diagnosis  
Making an accurate diagnosis of PD is difficult, as there is no standard diagnostic test 
available. Because PD symptoms occur due to decreased dopamine levels, one possible test is 
to administer the drug Levodopa (L-Dopa/L-3,4-dihydroxyphenylalanine) to the patient and 
monitor the response to the treatment. Significant improvement with this medication often 
confirms the diagnosis of PD.  
However, there are additional imaging techniques to analyze brain activity, which can be 
applied to support diagnostics. At present, either PET (Positron Emission Tomography) or 
DaT (Dopamine Transporter) scans help to distinguish between the different diseases linked 
to Parkinsonian symptoms. First, the patient receives an injection of an imaging agent, which 
can be visualized by a special detector. Then, the scan measures either glucose metabolism or 
dopamine transporter activity in the brain. If the measured activity is reduced in the patient 
compared to a control brain and can be elevated by a drug like L-Dopa, the diagnosis of PD is 
likely (Fig. 4) [www.parkinson.org].  
Moreover, there is evidence from numerous studies that impairment of olfaction is a 
characteristic and early feature of PD. Deficits in the sense of smell may precede clinical 
motor symptoms by years and can be used to assess the risk for developing PD in otherwise 
asymptomatic individuals. It was observed that over 95% of patients with PD displayed 
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significant olfactory loss. Thus, olfactory dysfunction should be considered as a reliable 
diagnostic marker of the disease [Haehner 2009]. 
 
Fig. 4: PET scans from a healthy and a PD-affected individual. Top panel: normal scan, middle panel: 
abnormalities in the putamen (red uptake in the figure) in a patient with Parkinson’s Disease, lower panel: a 
return to an almost normal scan following the introduction of levodopa. [parkinson.org]. 
 
f) Therapy 
Currently, no treatment is available to cure Parkinson’s Disease. However, there are drugs to 
treat both motor and non-motor symptoms associated with PD. Most of the therapeutic 
approaches focus on the compensation of the dopaminergic deficit, thereby alleviating the 
cardinal symptoms of the disease. Soon after the discovery of the nigral dopamine loss 
occurring in PD, treatment with the dopamine precursor Levodopa revolutionized the therapy. 
For the last five decades, Levodopa has been seen as the gold-standard to treat the motor 
symptoms. In addition to L-Dopa, an inhibitor of the peripheral Dopamine decarboxylase 
(DDC), like Carbidopa, is administered (Fig. 5). This blocks peripheral conversion of L-Dopa 
and allows a high amount of applied L-Dopa to reach and pass the blood-brain barrier. Within 
the central nervous system, L-Dopa is then converted into dopamine in neurons. Besides this 
precursor molecule, dopaminergic agonists can be utilized to stimulate dopamine receptors or 
the dopamine catabolism can be blocked by monoamine oxidase B (MAO-B) inhibitors. 
MAO-B inhibitors intervene at the conversion of dopamine to 3,4-Dihydroxyphenylacetic 
acid (DOPAC) and are mostly used to treat mild symptoms of PD. Another possibility is to 
use catechol-O-methyl-transferase (COMT) inhibitors which reduce the methylation of L-
Dopa and dopamine and thereby increase the bioavailability of these substances. One critical 
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aspect regarding the application of the mentioned drugs is the appearance of severe non-motor 
side effects like psychiatric disorders and fatigue. Severe side effects also occur when 
anticholinergic drugs are administered for some tremor cases. 
 
Fig. 5: Dopamine metabolism.   
The neurotransmitter Dopamine originates from the amino acid tyrosine and the precursor L-Dopa. Dopamine is 
either processed by the enzymes MAO/COMT via oxidation/methylation or by the Dopamine-B-hydroxylase. 
[http://www.smartdraw.com/examples/view/neurology+of+dopamine+metabolism] 
 
For treatment of non-motor symptoms, Clozapine is the most efficient antipsychotic agent in 
PD patients, but due to the possible development of agranulocytosis, Quetiapine is the first-
line antipsychotic drug being used. 
Besides medication, another option for some PD patients is deep brain stimulation (DBS). 
Medical surgery and introduction of microelectrodes in specific regions of the basal ganglia 
can only be offered to few patients who fulfill several criteria [Smith 2012]. 
Unfortunately, the goal to provide neuroprotective interventions, which would be able to 
modify the progression of Parkinson's Disease, has not been met over the last decades, despite 
potentially encouraging results with compounds, such as Rasagiline [Rascol 2011]. 
 
g) Neuropathology 
One characteristic feature of PD is the preferential loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc) projecting to the striatum. The hormone and 
neurotransmitter dopamine, which belongs to the family of catecholamines, is involved in the 
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regulation of voluntary movements. As a consequence, high dopamine levels lead to high 
levels of motor activity, while low levels of dopamine lead to slowed movement. 
Cell death of dopaminergic neurons, which convert dopamine to a dark-pigmented product 
called Neuromelanin, leads to depigmentation of the substantia nigra. This phenomenon can 
be investigated in post mortem brains of PD patients. PD symptoms occur when 
approximately 80% of striatal dopamine are depleted [Winklhofer 2007]. 
It should be noted that the neurodegenerative process is not limited to dopaminergic neurons. 
In addition, noradrenergic, serotonergic and cholinergic systems, the cerebral cortex, brain 
stem, spinal cord and the peripheral autonomic nervous system are also affected [Pilsl and 
Winklhofer 2011]. 
A further pathologic hallmark of PD is the presence of Lewy bodies and Lewy neurites 
containing aggregated α-Synuclein as a main component [Spillantini 1997]. On the one hand, 
Lewy bodies could implicate a protective function via sequestration of toxic misfolded protein 
species. On the other hand, they could provide a reservoir for toxic protein species. 
Importantly, Lewy bodies are not present in all Parkinsonian syndromes, leading to the 
conclusion that PD comprises diverse disease forms [Pilsl and Winklhofer 2011]. 
 
1.1.2 Features of the E3 ubiquitin ligase Parkin 
a) Modular structure of Parkin 
The Parkin gene encodes a protein consisting of 465 amino acids and a molecular weight of 
52 kDa [Kitada 1998]. The gene shares a bidirectional promoter with the Parkin-coregulated 
gene (PACRG), which is transcribed on the opposite strand in the opposite direction 
[Lockhart 2004]. Similarly to PINK1, Parkin is ubiquitously expressed and high expression 
levels were found in the brain, heart, skeletal muscle and testis. Surprisingly, Parkin shows 
only low expression in the substantia nigra pars compacta [Kitada 1998]. Within cells, 
Parkin is localized in the cytoplasm [Shimura 1999].  
The modular structure of Parkin contains several structural elements: a ubiqutin-like (UBL) 
domain at the N-terminus and a RING-between-RING (RBR) domain at the C-terminus (Fig. 
6). This RBR domain consists of two different RING (Really Interesting New Gene) domains 
- RING1 and RING2 - and an IBR (in-between RING) domain. An additional, atypical RING 
domain - RING0 - was identified lying N-terminal to the RBR domain. As Parkin contains an 
RBR motif, it belongs to the RBR class of E3 ubiquitin ligases [Wenzel and Klevit 2012]. 
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Fig. 6: Domain architecture of Parkin. UBL: ubiquitin-like, RING: really interesting new gene, IBR: in-
between RING, REP: repressor element of Parkin. Numbers indicate amino acid residues [Winklhofer 2014]. 
 
Altogether, the structure of Parkin is formed in a relatively compact manner with two 
occluded regions: the active site cysteine in RING2 (C431) and the E2-binding site in RING1 
are not accessible, indicating an autoinhibited state (Fig. 7). The phemomenon of 
autoinhibition was also reported for other E3 ubiquitin ligases, such as HHARI (Human 
Homolog of Drosophila Ariadne-1), HOIP (HOIL-1-interacting protein) and HOIL-1L (haem-
oxidized IRP2 ubiquitin ligase 1), which points to autoinhibition as a general feature of RBR 
ligases. However, the inhibitory mechanisms differ between these RBR ligases [Winklhofer 
2014]. 
 
Fig. 7: Schematic structure of Parkin. The compact structure of Parkin represents an autoinhibited state with 
an inaccessible E2-binding site in RING1 and occluded C431 in RING2 [Winklhofer 2014]. 
 
b) RBR E3 ligase mechanism 
Ubiquitination is carried out by a trio of enzymes: an E1 ubiquitin-activating enzyme, an E2 
ubiquitin-conjugating enzyme and an E3 ubiquitin ligase. In humans, the number of E3 
ligases with over 600 greatly exceeds the number of E2 enzymes with less than 40, which 
underscores their role in substrate selection [Wenzel and Klevit 2012]. 
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E3 ligases are divided into three groups: RING, HECT (homologous with E6-associated 
protein C-terminus) and RBR (RING-between-RING) ligases. Parkin belongs to the RBR 
class of E3 ubiquitin ligases (Fig. 8), which consists of 14 complex multidomain enzymes 
[Smit and Sixma 2014]. Other well-known candidates of RBR E3 ubiquitin ligases are HOIP 
and HOIL-1L, which are components of the multiprotein complex LUBAC [Spratt 2014]. 
 
 
Fig. 8: Domain organisation of the RBR E3 ligases Parkin, HHARI, TRIAD1, HOIP and HOIL-1L. UBL: 
ubiquitin-like, acidic, Gly: glycine-rich, ZF: zinc finger, UBA: ubiquitin-associated, R1: Ring 1, IBR : in-
between RING, R2: Ring 2. Only HHARI, TRIAD1 and HOIP contain an Ariadne or linear ubiquitin 
determining domain (LDD) [Smit 2014]. 
 
The RBR E3 ubiquitin ligases use a hybrid mechanism combining features of RING and 
HECT ligases to transfer ubiquitin to substrate proteins (Fig. 9). RING ligases are known to 
facilitate the direct transfer of ubiquitin from a ubiquitin-charged E2 to the substrate, whereas 
HECT ligases form a thioester intermediate with ubiquitin via a catalytic cysteine residue. In 
a following step, the ubiquitin moiety is transferred to the lysine residue of a target protein by 
generation of an isopeptide bond. The RING/HECT hybrid mechanism of RBR E3 ligases 
comprises the binding of an E2 ubiquitin-conjugating enzyme via RING1 as seen in RING 
ligases and the transfer of the ubiquitin from E2 to a catalytic cysteine residue in RING2 
forming a transient thioester intermediate like described for HECT ligases [Wenzel and Klevit 
2012, Winklhofer 2014]. 
This hybrid mechanism of RBR ligases was first identified in HHARI [Wenzel 2011]. In 
contrast to Parkin and HOIP, HHARI contains an additional Ariadne domain at its C-
terminus, which blocks access to the catalytic cysteine residue in the RBR domain and is 
thereby responsible for an intramolecular autoinhibition mechanism. 
Showing structural and functional similarities to Parkin, HHARI is suggested as a possible 
candidate to compensate for the loss of Parkin function in other neurons than dopaminergic 
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ones. Furthermore, endogenous HHARI was found in Lewy bodies of both PD and diffuse 
Lewy body disorder patients [Parelkar 2012]. 
 
 
Fig. 9: Mechanism of ubiquitin transfer mediated by RING, HECT or RBR ligases. Three enzymes 
cooperate to accomplish ubiquitination: E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme and 
E3 ubiquitin ligase. RBR ligases combine features of the RING and HECT ligases by binding of an E2 ubiquitin-
conjugating enzyme via RING1 like seen in RING ligases and the transfer of the ubiquitin from E2 to a catalytic 
cysteine residue in RING2 forming a transient thioester intermediate like reported for HECT ligases. 
[Winklhofer 2014] 
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c) Pathogenic mutations 
So far, more than 120 different pathogenic Parkin mutations have been described, which 
account for most cases of autosomal-recessive Parkinsonism. Various types of mutations were 
identified: missense mutations, nonsense mutations and exonic rearrangements like 
duplications or deletions [www.molgen.ua.ac.be/PDmutDB]. 
Although the mutations are distributed over almost the whole gene, clusters of mutations can 
be found in the functional domains pointing to the significance of these regions. A loss-of-
function mechanism was suggested for pathogenic Parkin mutations by genetic and 
biochemical studies, whereby the mutations are thought to impact either intramolecular or 
interactions with E2, substrate or adaptor proteins. Parkin folding and stability or catalytic 
activity could also be affected by the mutations [Winklhofer 2014].  
 
d) Parkin-deficient animal models 
Parkin-deficient mice do not develop nigrostriatal neurodegeneration, but evidence for 
mitochondrial alterations was described in several reports. Parkin knock-out (KO) mice show 
decreased levels of proteins which are involved in mitochondrial function or oxidative stress 
response in the ventral midbrain [Dawson and Dawson 2010, Palacino 2004]. Parkin KO mice 
do not recapitulate the human phenotype of PD, which could be explained by compensatory 
mechanisms through other E3 ubiquitin ligases. 
In contrast, Parkin- as well as PINK1-deficient flies show a clear phenotype with reduced life 
span, male infertility, locomotor deficits and flight muscle degeneration [Pilsl and Winklhofer 
2011]. Intriguingly, genetic interaction studies revealed that Parkin was able to rescue the 
PINK1 loss-of-function phenotype but not vice versa. This observation suggests a position of 
PINK1 upstream of Parkin within the same pathway [Clark 2006, Park 2006, Yang 2006, 
Exner 2007]. 
 
e) Function and putative substrates of Parkin 
With its characteristic RBR domain, Parkin is assigned to the RBR E3 ubiquitin ligases and 
supposed to play a crucial role in ubiquitination. Ubiquitination is a post-translational 
modification that determines the fate of many proteins in the cell, as this process is involved 
in cell-cycle progression, transcriptional regulation, DNA repair, signal transduction and 
protein turnover by the proteasome [Wenzel and Klevit 2012, Spratt 2014]. 
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Ubiquitin molecules are linked via their C-terminal glycine residue to the ε-amino group of a 
lysine residue belonging to the target protein or another ubiquitin molecule. Different modes 
of ubiquitination exist to target the proteins for different purposes. Monoubiquitination 
(attachment of a single ubiquitin molecule), multi- (attachment of several single ubiquitin 
molecules) and polyubiquitination (attachment of ubiquitin chains) can be discriminated (Fig. 
10) [Sadowski 2012].  
 
 
Fig. 10: Proteins may be ubiquitinated in diverse ways: mono-, mulit-, poly- and linear ubiquitination as 
well as combinations thereof.  [http://sysimg.ifrec.osaka-u.ac.jp/udb/about.html] 
 
Furthermore, ubiquitin has seven lysine residues, opening the possibility of forming seven 
different linkage types, namely K6, K11, K27, K29, K33, K48 and K63. Besides, a donor 
ubiquitin can also be attached to an acceptor ubiquitin via the amino terminal methionine 
(M1) resulting in the formation of M1- or linear linkages, making a total of eight different 
inter-ubiquitin linkage types [Zinngrebe 2014]. Each linkage type fulfills a different 
physiological function (Fig. 11): K48-linkage targets proteins for proteasomal degradation, 
while K63-linkage is required for cell signaling in DNA damage response, endocytosis and 
kinase activation and preferentially involved in the lysosomal pathway. The roles of the other 
atypical linkag types are not yet fully understood. K11-linkage, for instance, was connected to 
proteasomal degradation. Linear ubiquitination is catalyzed by a complex called linear 
ubiquitin chain assembly complex (LUBAC) and associated with NF-κB signaling [Sadowski 
2012, Zinngrebe 2014]. 
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Fig. 11: Different modes of ubiquitination lead to different substrate fates. 
[http://cshperspectives.cshlp.org/content/2/12/a006734/F5.expansion.html] 
 
Although Parkin is known to be an E3 ubiquitin ligase, the intriguing question of key 
substrates is still unanswered. The long list of putative substrates includes α-Synuclein, Pael-
R and CDCrel-1, all of which accumulate in patients with heritable Parkinson’s Disease. They 
point to a role for Parkin in the clearance of misfolded or aggregated proteins. But none of 
them could so far serve as an explanation for the selective death of dopaminergic neurons. 
Mitofusin-1 and -2, being regulators of mitochondrial dynamics, are two other reported 
substrates for ubiquitination by Parkin [Wenzel and Klevit 2012]. 
In 2011, PARIS (Parkin-interacting substrate) was identified as a new Parkin substrate. It was 
reported that Parkin regulates the expression levels of PARIS through the ubiquitin-
proteasome system. PARIS in turn binds to the promoter of the mitochondrial regulator PGC-
1α (peroxisome proliferator-activated receptor gamma-coactivator 1-alpha) to inhibit its 
expression. Consequently, degradation of PARIS by Parkin leads to increased gene 
expression of PGC-1α and mitochondrial biogenesis, whereas loss of Parkin leads to 
accumulation of PARIS and thereby repressed PGC-1α expression [Shin 2011, Winklhofer 
2014]. 
 
f) Parkin as tumor suppressor gene 
Studies from PD resesarch demonstrate an antiapoptotic effect of Parkin under stress 
conditions [Henn 2007, Bouman 2011]. In contrast, cancer studies suggest a role of Parkin as 
a tumor suppressor gene (TSG) [Cesari 2003]. During the last few years, Parkin has been 
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linked to cancer, as mutations in this gene were found in several different cancer types. One 
study underpinning the role of Parkin as a TSG demonstrated that Parkin mutations in cancer 
cells decrease its E3 ubiquitin ligase activity. The authors argued that the ability of Parkin to 
ubiquitinate and degrade Cyclin E was compromised in cancer cells leading to mitotic 
instability of the cells [Veeriah 2010]. 
A general link between neurodegenerative diseases and cancer was assumed because some of 
the genes involved in neurodegenerative disorders play a central role in cell cycle control, 
DNA repair and kinase signaling. Furthermore, genetic studies have shown a reduced 
incidence of some cancer types, such as lung cancer, but an increased incidence of other 
cancer types, such as breast and skin cancer, in people suffering from Parkinson’s Disease 
[Plun-Favreau 2010, Olsen 2005]. As NF-κB and the signaling pathways that are involved in 
its activation are also important for tumor development, the NF-κB network might represent a 
an additional link between neurodegeneration and cancer [Karin 2002]. Furthermore, the 
cytokine TNF-α, which can induce activation of the NF-κB pathway, is known to be a multi-
functional regulator of diverse pathways, which can induce pro-apoptotic as well as anti-
apoptotic cell responses [Park and Bowers 2010]. 
 
g) Neuroprotective potential of Parkin 
The neuroprotective activity of Parkin has been observed in several cellular and animal 
models, which proved that Parkin protects from cell death in stress paradigms like 
mitochondrial, ER (endoplasmatic reticulum) or proteotoxic stress. Parkin is transcriptionally 
upregulated when cells are exposed to various stress conditions, indicating its neuroprotective 
function. In addition, Parkin deficiency leads to an increased vulnerability under stress 
conditions [Henn 2007, Bouman 2010, Müller-Rischart 2013]. 
In principal, there are at least three hypotheses how Parkin could mediate its neuroprotective 
activity: I) promoting the removal of damaged mitochondria via mitophagy; II) increasing 
proteasomal degradation of toxic substrates; and III) modulating nondegradative ubiquitin 
signaling within cell death or cell viability pathways. These alternatives require either the 
interaction of Parkin and PINK1 to induce autophagic clearance of depolarized mitochondria, 
ubiquitination and proteasomal degradation of Parkin substrates or the influence of a general 
prosurvival pathway like NF-κB and a proapoptotic pathway like caspase signaling 
[Winklhofer 2014]. 
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1.1.3 Parkin, PINK1 and mitochondria 
Mitochondria are extremely dynamic organelles whose morphology is determined by fusion 
and fission events. Mitochondrial fusion is controled by Mitofusin 1 and 2 (Mfn1 and 2) 
located in the outer mitochondrial membrane and OPA1 (Optic atrophy 1) located in the inner 
mitochondrial membrane. OPA1 is regulated by alternative splicing and proteolysis, which 
produce several long and short OPA1 isoforms. The cytosolic protein Drp1 (Dynamin-related 
protein 1) and the mitochondrial-anchored protein Fis1 (Mitochondrial fission 1) are GTPases 
and regulate fission events.  
Well-balanced mitochondrial dynamics lead to tubular mitochondrial network, whereas 
increased fission produces small rod-like or spherical mitochondria and increased fusion 
generates elongated, strongly interconnected mitochondria. An imbalance of the fusion and 
fission machinery implicates severe effects on mitochondrial bioenergetics, transport and 
clearance [Pilsl and Winklhofer 2011]. 
In the last decade, PD-associated genes have been linked to effects on mitochondrial 
dynamics. Transient silencing of PINK1 as well as Parkin expression in cell culture models 
results in increased mitochondrial fragmentation and decreased mitochondrial ATP 
production. This phenotype can be rescued by overexpression of the fusion proteins Mfn2 or 
OPA1. Moreover, Parkin and PINK1 protect cells from mitochondrial fragmentation caused 
by overexpression of the fission factor Drp1 [Lutz 2009]. These findings provide a link of the 
PD-associated genes Parkin and PINK1 with factors controling mitochondrial fusion and 
fission events. 
Parkin and PINK1 also have a different effect on mitochondria by assisting in their 
autophagic clearance. Upon treatment of cells with CCCP and disruption of the mitochondrial 
membrane potential, Parkin and PINK1 collaborate to attract the autophagosomal machinery 
for clearance of damaged mitochondria (mitophagy). However, the role of mitophagy has to 
be addressed in future in vivo models to prove its relevance for disease progression. 
The detailed mechanism how Parkin executes its protective effects on mitochondria is still not 
fully understood. A convincing concept is the context- and tissue-specificity of Parkin 
function: Under mild stress conditions, Parkin could prevent mitochondrial fragmentation. 
When the stress level exceeds a certain limit and severe damage of mitochondria has taken 
place, Parkin could promote the elimination of these defective organelles via mitophagy 
[Winklhofer 2014]. 
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1.2 Huntingtin 
1.2.1 Huntington’s Disease 
a) History 
Huntington’s Disease (HD) is a rare neurodegenerative disease with a prevalence of 5-7 in 
100,000 in Europe [Huntington Study Group 2011]. It is the most common genetic cause of 
abnormal involuntary writhing movements called chorea. The term “chorea” is derived from 
the Greek word for “dance”, as the movements of the feet or hands are comparable to dancing 
movements. George Huntington was the first one to provide a thorough description of this 
disease in 1872 (Fig. 12). He examined the combined medical history of several generations 
of a family exhibiting similar symptoms and realized that their conditions must be linked 
[Huntington 1872]. In 1993, the disease-associated gene Huntingtin was identified [The 
Huntington’s Disease Collaborative Research Group, 1993]. 
 
 
 
Fig. 12: George Huntington (1850 - 1916) and the first description of Huntington’s Disease „On Chorea“. 
[http://en.wikipedia.org/wiki/File:On_Chorea_with_photo.jpg] 
 
b) Etiology 
HD is caused by a single genetic factor: an autosomal dominant mutation in the Huntingtin 
gene. An abnormal expansion of a CAG triplet repeat (>36) in this gene leads to the formation 
of a mutant protein with an expanded polyglutamine (polyQ) tract (Fig. 13) [Rubinsztein 
1996]. Due to this elongation of the polyQ stretch, the mutant protein is prone for 
aggregation. Interestingly, there is an inverse correlation between the length of the polyQ tract 
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and the age of onset for HD symptoms, while the length of the polyQ stretch directly 
correlates with the severity of the symptoms [Andrew 1993]. In contrast to other 
neurodegenerative diseases, polyQ diseases are always inherited and do not occur 
sporadically.  
   
Fig. 13: Comparison of normal and mutant Huntingtin protein. Individuals expressing a normal Huntingtin 
protein with a repeat length of 10-36 (left) are not affected by Huntington's disease, whereas individuals 
expressing a mutated form of the protein with repeat lengths larger than 36 (right) are affected. 
[https://embryology.med.unsw.edu.au/embryology/index.php?title=File:Healthy_Huntingtin_protein_and_Hunti
ngtin_gene_mutated_by_Huntington%27s_Disease.jpg] 
 
c) Symptoms 
The first symptoms of HD are uncontrollable movements (choreic movements). When the 
disorder progresses, more severe physical symptoms like rigidity, writhing motions or 
abnormal posturing appear. Non-motor symptoms such as cognitive impairment, memory 
deficits and depression accompany the progression of the disease. 
 
d) Diagnosis  
Medical diagnosis of the onset of HD is often made by following the appearance of physical 
symptoms specific to the disease. Futhermore, genetic testing can also be used to confirm a 
physical diagnosis if there is no family history of HD. The genetic test for HD consists of a 
blood test determining the numbers of CAG repeats in each of the Huntingtin alleles. 
 
e) Therapy 
Similar to PD, there is no cure for HD, but there are treatments available to reduce the 
severity of some of its symptoms. In 2008, Tetrabenazine was approved in the US for 
treatment of chorea in Huntington's disease [Hayden 2009]. Additionally, rigidity can be 
treated with antiparkinsonian drugs. 
 
f) Neuropathology 
In parallel to PD, HD is also characterized by the loss of specific neurons. However, the most 
affected region in HD is the striatum (with 50-60% loss in the Nucleus caudatus and the 
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Putamen in advanced disease, Fig. 14). Besides, cerebellar atrophy is most frequently 
reported in cases with a juvenile onset of the disease [Rubinsztein and Carmichael 2003]. The 
loss of striatal neurons leads to decreased levels of the neurotransmitter GABA (γ-
aminobutyric acid), which serves as an inhibitory signal and influences Dopamine levels. A 
drop in GABA levels causes an imbalance in the regulation of movements. 
 
 
Fig. 14: Huntington’s Disease is characterized by a specific loss of neurons in the striatum (Nucleus 
caudatus and Putamen). The left panel shows a normal brain with clearly visible Nucleus caudatus and 
Putamen, whereas the right panel shows one hemisphere of a HD patient brain with mild atrophy of the Nucleus 
caudatus. [http://tidsskriftet.no/article/1730507; Thomas Arzberger]  
 
An additional pathological feature of HD is the presence of protein aggregates. In post 
mortem brains, neuronal intranuclear inclusions (NIIs) are found, which contain an N-
terminal fragment of Huntingtin [DiFiglia 1997]. Besides, extranuclear aggregates like 
neuropil aggregates and cytoplasmic aggregates were also observed [Gutekunst 1999, 
Hackam 1999]. 
 
1.2.2 Features of Huntingtin 
a) Modular structure of Huntingtin 
The Huntingtin (Htt) gene contains 67 Exons with a polyQ region located in Exon1 [Ambrose 
1994]. In healthy individuals, the polyQ region consists of up to 36 repeats. Additionally, 
Huntingtin features a high number of HEAT repeats (Huntington, Elongation Factor 3, 
PR65/A, TOR) and a putative nuclear export signal (NES) near the C-terminus (Fig. 15). The 
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multiple cleavage sites for caspases and other proteases lead to the formation of several N-
terminal fragments [Ross and Tabrizi 2011]. 
 
 
Fig. 15: Domain structure of Huntingtin. Human Huntingtin predominantly consists of HEAT repeats. A 
polyglutamine stretch (polyQ) is located at the N-terminus and a nuclear export signal (NES) in proximity to the 
C-terminus. Furthermore, proteolytic cleavage by caspases and other proteases forms N-terminal fragments 
[Ross and Tabrizi 2011]. 
 
b) Huntingtin-deficient and -overexpressing animal models 
As Huntingtin KO mice die already at the embryonic stage before day 8.5 [Duyao 1995], this 
points to a putative role of Htt in embryonic development. Besides that, mice with less than 
50% of wild-type (WT) Huntingtin display defects in neurogenesis and formation of the 
cortex and striatum [White 1997]. 
The best characterized mouse model for HD is the R6/2 mouse line, which expresses an N-
terminal fragment of Huntingtin with an extended polyQ stretch and shows motoric 
impairment and reduction of brain size and weight after two months. After 12 months, these 
transgenic mice develop first signs of neurodegeneration [Mangiarini 1996, Turmaine 2000]. 
Both intranuclear inclusions as well as neuropil aggregates were observed in this mouse line 
[Davies 1997, Li 1999]. 
Moreover, HD mouse models expressing the full-length Htt gene carried by either a yeast or a 
bacterial artificial chromosome (YAC or BAC) exist. However, these full-length transgenic 
models show relatively normal survival rates and a gradual development of the disease over 
many months in contrast to N-terminal transgenic models with shortended life spans and early 
development of the disease. 
Another group of HD models consists of knock-in (KI) models, which are generated by 
homologous recombination using mouse embryonic stem cells. Similar to HD patients, these 
KI mice are heterozygous for one wild-type Huntingtin allele and one CAG-expanded allele. 
In summary, the KI models display milder initial behavioral abnormalities than transgenic 
lines and normal life spans [CHDI Foundation, Jackson Laboratory 2014]. 
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c) Putative function of wild-type and malfunction of mutant Huntingtin 
To date, the cellular function of Huntingtin is still unclear. Whether neuronal degeneration in 
HD is due to the loss of normal Htt function or due to a toxic gain of function, or both, is not 
fully understood [Roze 2011]. 
Wild-type Htt is a ubiquitously expressed protein present in most cells of the organism [Sharp 
1995]. It is mostly located in the cytoplasm and was reported to shuttle into the nucleus. 
Multiple interaction partners like HAP1 (Huntingtin-associated protein 1), HIP-1 (Huntingtin-
interacting protein 1) or PGC-1α were described for Huntingtin [Li 1995, Kalchman 1997, 
Ross and Tabrizi 2011]. Several transcription factors such as CREB (cAMP response 
element-binding protein) were also reported as binding partners of Htt. The Htt protein is 
considered to be a scaffold protein, which orchestrates intracellular trafficking, signaling 
pathways and transcriptional activity being requirements for neuronal homeostasis [Roze 
2011]. 
Due to the extended polyQ stretch, mutant Huntingtin shows increased formation of β-sheets 
and aggregates. One possibility is that these aggregates sequester either wild-type Htt or 
interaction partners and thereby influence the fate of neuronal cells. Another important aspect 
of Huntingtin aggregates is their effect on the ubiquitin-proteasome system (UPS). On the one 
hand, UPS components were found in polyQ aggregates of HD transgenic mice and HD post 
mortem brains suggesting a sequestration of these components. On the other hand, polyQ 
containing aggregates cannot be cleared by the UPS machinery and may block the proteasome 
resulting in insufficient degradation of other proteins [Davies 2007, Roze 2011]. 
 
d) Neuroprotective potential of Huntingtin 
Interestingly, Huntingtin exhibits a neuroprotective potential like Parkin. Rigamonti and co-
workers showed that WT Htt protects CNS cells from a variety of apoptotic stimuli 
[Rigamonti 2000]. In vivo experiments with overexpression of WT Htt confirmed a 
significant protection against NMDAR (N-methyl-D-aspartate receptor)-mediated apoptotic 
neurodegeneration. Therefore, Huntingtin may regulate the balance between neuronal survival 
and death following acute stress conditions and the levels of Huntingtin may modulate 
neuronal sensitivity to excitotoxic neurodegeneration [Leavitt 2006]. 
A couple of mechanisms were proposed how this neuroprotective potential might be carried 
out. First, WT Htt was reported to interfere with the activity of the apoptosome and thereby 
inhibiting neuronal cell death. Cells overexpressing WT Htt showed continuous cytochrome c 
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release, but no processing of Procaspase-9 upon exposure to apoptotic stimuli [Rigamonti 
2001]. 
Second, the production of the neurotrophic factor BDNF (brain derived neurotrophic factor) 
was found to be regulated by WT, but not mutant Huntingtin. BDNF is involved in synaptic 
glutamate release and excitotoxicity [Zuccato 2001, Zuccato 2003]. Moreover, WT Htt 
promotes the axonal transport of BDNF from cortical neurons and the release of BDNF into 
the striatum [Gauthier 2004].  
Third, data focusing on the proapoptotic molecule HIP-1 suggest that sequestration of HIP-1 
underlies the antiapoptotic effect of Htt. Normally, HIP-1 is associated with Huntingtin, 
whereas an expansion of the polyglutamine stretch in Huntingtin leads to reduced binding of 
HIP-1. Free HIP-1 can then bind to the protein HIPPI (Hip-1 protein interactor) and together 
they form a heterodimer. In the following step, this heterodimer is thought to recruit 
Procaspase-8 and thereby induce apoptosis, which might explain the death of neuronal cells in 
HD [Gervais 2002]. 
 
1.2.3 Huntingtin and mitochondria 
Mitochondrial dysfunction and energy deficits have been found in multiple analyses of post 
mortem HD patient brains as well as mouse and cell culture models. These analyses comprise 
altered mitochondrial morphology (Fig. 16), Ca
2+
 buffering capacity, enzymatic activity 
(complex II/III/IV), membrane potential, ATP levels and transport processes [Damiano 2010, 
Reddy and Shirendeb U.P. 2012, Costa and Scorrano 2012]. 
 
Mitochondria play an essential role during apoptosis, as these organelles sense cell damage 
and release cytochrome c accompanied by mitochondrial fragmentation and christae 
remodeling [Danial and Korsmeyer 2004, Frank 2001]. Furthermore, neurons rely mainly on 
ATP production of mitochondria, as they cannot switch to glycolysis, which makes them 
extremely susceptible to mitochondrial dysfunction. Due to their extensive physiological 
functions including a fluctuating plasma membrane potential, release and uptake of 
neurotransmitters as well as trafficking of organelles, neurons also exhibit especially high-
energy demands [Mitchell 1999, Pickrell 2011]. A large number of neurodegenerative 
disorders share similar mitochondrial alterations [Bossy-Wetzel 2003], implying the 
importance of mitochondrial integrity to the development of HD.  
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Fig. 16: HD lymphoblasts and striatal precursors show mitochondrial fragmentation (left) and cristae 
derangement (right).  Left: Lymphoblasts from HD patients carrying extendended polyQ tracts of 48, 70 or 
45+47 reveal fragmentation and clustering of mitochondria compared to wt controls. Right: Electron 
micrographs of Q111 striatal neurons from Htt knockin mice show altered mitochondrial cristae structure 
compared to wt neurons. [Costa 2010] 
 
Specific interactions of mitochondrial proteins or regulators with Htt have been described in 
the last decade (Fig. 17). Several investigations imply a link between transcriptional 
dysregulation and defects in energy metabolism demonstrated in patient’s brain tissue and HD 
transgenic mice. PGC-1α is a master regulator of mitochondrial biogenesis and oxidative 
phosphorylation. First evidence for a role of PGC-1α in the pathogenesis of HD came from 
observations of PGC-1α null mice revealing selective striatal lesions. Moreover, PGC-1α 
levels and activity are reduced in different models of HD. In neuronal cells, a direct link 
between CREB phosphorylation and transcriptional regulation of the PGC-1α promoter was 
established. For instance, stimulation of extracellular NMDA receptors in HD neuronal cells 
with impaired CREB/ PGC-1α signaling increases cell vulnerability [Lin 2004, Cui 2006, 
Okamoto 2009]. The transcriptional coactivator PGC-1α displays an interesting overlap 
between HD and PD, as both Htt as well as Parkin have been connected to this mitochondrial 
regulator in the past years. 
In addition to PGC-1α, Drp1 was identified as an interactor of mutant Htt. This interaction 
between the fission-promoting factor and the polyQ protein stimulates the GTPase activity of 
Drp1. A dominant-negative Drp1 mutant with reduced GTPase activity rescues mitochondrial 
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fragmentation, transport defects and neuronal cell death caused by mutant Htt [Costa 2010, 
Song 2011].  
Recently, the group around Robert Friedlander discovered an interaction between mutant Htt 
and TIM23 (translocase of the inner membrane, subunit 23). Mitochondrial protein import 
was impaired by mutant Htt in a presymptomatic HD stage and the import defect and 
neuronal cell death could be rescued by overexpression of TIM23 complex subunits [Yano 
2014]. 
 
Fig. 17: Functional alterations in HD mitochondria.  The cartoon depicts the functional alterations occurring 
at the level of mitochondrial function, opening of the permeability transition pore (PTP) and morphology in the 
context of HD. Mutated Huntingtin can act at the transcriptional level through inhibiton of PGC-1α, directly at 
the mitochondrial level, by increasing the opening probability of the PTP and affecting mitochondrial respiratory 
chain. Moreover, mutant Htt can also influence DRP1 causing fragmentation and remodeling of the 
mitochondrial cristae. [Costa and Scorrano 2012] 
 
1.2.4 Huntingtin and Parkin 
With Parkin being involved in ubiquitination and degradation of substrate proteins and Htt 
showing high resistance to degradation processes, the question arised, if Parkin deficiency 
would deteriorate the HD phenotype in mouse models. To address this question in a first 
attempt, Parkin null mice were crossed with an HD mouse model (R6/1) and the results 
indicated a slightly more severe HD phenotype, when Parkin expression was partially 
suppressed [Rubio 2009]. It had already been observed before that Parkin is able to facilitate 
the elimination of expanded polyglutamine proteins. Experiments with a polyQ Ataxin-3 
fragment suggested a role for Parkin in the preservation of proteasomal function [Tsai 2003]. 
These findings hint at a possible protective role of Parkin in HD. 
Introduction 
27 
 
1.3 TNF-α stimulated pathways 
In 1984, Aggarwal and coworkers isolated and identified the two cytotoxic factors TNF-α and 
β (TNF: tumor necrosis factor) in macrophages and lymphocytes. Until now, 19 members of 
the TNF superfamily and 29 TNF receptors (TNF-R) have been identified. The TNF 
superfamily members participate in inflammation, apoptosis, proliferation, invasion, 
angiogenesis, metastasis and morphogenesis with apparent roles in different diseases. 
Furthermore, these molecules represent attractive drug targets and TNF blockers are used for 
treatment of, amongst others, rheumatoid arthritis and osteoporosis. 
The disproportionate number of TNF ligands and receptors implies that some of the ligands 
interact with more than one receptor. For instance, TNF-α was reported to bind to two 
different receptors: TNF-R1 and TNF-R2. While TNF-R1 containing an intracellular death 
domain (DD) is expressed universally, the expression of TNF-R2 is only found in cells of the 
immune system, endothelial cells and nerve cells [Aggarwal 2003, Aggarwal2012].  
Being a type-II transmembrane protein, TNF-α is processed by proteolytic cleavage through 
TACE (TNF-α cleaving enzyme) resulting in a soluble form of TNF-α. Both exogenous 
signals including exposure to bacterial or viral proteins like LPS (lipopolysaccharide) as well 
as cell-intrinsic stimuli lead to increased TNF-α expression. The cytokine TNF-α is a multi-
functional regulator of diverse pathways, which can induce pro-apoptotic as well as anti-
apoptotic cell responses [Park and Bowers 2010]. In the following chapters, the three major 
underlying pathways of these opposing activites will be illuminated in more detail: NF-κB, 
JNK (c-Jun N-terminal kinase) and caspase signaling. 
 
1.3.1 NF-κB pathways 
Since the identification of the transcription factor NF-κB (nuclear factor κB) in 1986, 
intensive research revealed NF-κB as the central orchestrator of inflammation and immune 
responses by maintenance of prosurvival gene expression [Sen and 
Baltimore 1986]. To celebrate the tremendous progress made in 25 
years for understanding the role and regulation of NF-κB, Nature 
Immunology published a special edition with focus on NF-κB in 
2011 (Fig. 18). 
 
Fig. 18: Special edition of Nature Immunology featuring a series of specially 
commissioned review articles to mark the 25th anniversary of the discovery 
of NF-κB. [http://www.nature.com/ni/journal/v12/n8/covers/index.html] 
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The NF-κB family consists of five members: RelA (p65), RelB and c-Rel as well as the 
precursor proteins NF-κB1 (p105) and NF-κB2 (p100) being processed into p50 and p52, 
respectively. The different NF-κB transcription factors form homo- or heterodimers, which 
bind to NF-κB binding sites in gene promoters and enhancers to either induce or suppress 
transcription. A common feature of all NF-κB proteins is their Rel homology domain (RHD) 
located at the N-terminus for DNA binding, interaction with inhibitory proteins and 
dimerization [Oeckinghaus 2011, Hayden and Ghosh 2004].  
As a wide range of stimuli mediated by receptors like TNF-R, TLR(Toll-like receptor) or IL-
1R (interleukin 1 receptor) can induce NF-κB activation and dysregulation of this 
transcription factor is not only linked to inflammatory, autoimmune and metabolic diseases, 
but also cancer, NF-κB activity has to be tightly regulated by multiple elements. Therefore, 
one regulatory mechanism includes that NF-κB dimers are present in an inactive state in the 
cytoplasm by binding to IκB (inhibitor of κB) proteins [Hayden and Ghosh, 2012]. 
 
a) Canonical and noncanonical NF-κB signaling 
In general, there exist two main NF-κB-activating pathways in cells (Fig. 19). First, the more 
prominent canonical or classical pathway, which is activated via cytokine receptors like TNF-
R or IL-1R and pattern-recognition receptors like TLR, and dependent on IKKβ (IκB kinase) 
and the regulatory subunit NEMO (NF-κB essential modifier/IKKγ). This pathway mainly 
results in phosphorylation and degradation of IκB-α followed by nuclear translocation of p65-
containing dimers and activation of target gene transcription. Second, the noncanonical or 
alternative pathway, which is induced by specific TNF family members like CD40R (CD40 
receptor) or LTβR (lymphotoxin-β receptor). The noncanonical pathway depends on 
activation of IKKα and phosphorylation of p100 being associated with RelB. Processing of 
p100 by the proteasome generates a heterodimeric complex of p52 and RelB translocating to 
the nucleus. Next, down-regulation of NF-κB activation is achieved by a well-characterized 
feedback loop: newly synthesized IκB-α protein binds to nuclear NF-κB, which is exported to 
the cytosol. In both pathways, the proteasome plays an essential role. However, within the 
classical pathway it is responsible for degradation of IκB-α and in the alternative pathway for 
constitutive processing of p100 [Oeckinghaus 2011, Hayden and Ghosh 2012].  
 
Introduction 
29 
 
 
Fig. 19: The canonical and noncanonical pathway for activation of NF-κB. 
The canonical pathway (left) is induced by most physiological NF-κB stimuli such as TNF-R1 signaling. 
Stimulation of TNF-R1 leads to binding of TRADD (Tumor necrosis factor receptor type 1-associated death 
domain), FADD (FAS-associated death domain) and TRAF2 (TNF receptor-associated factor 2). TRAF2 
associates with RIP1 for IKK activation. In the following, IκBα is phosphorylated in an IKKβ- and NEMO-
dependent manner, which results in nuclear translocation of mostly p65-containing heterodimers and initiation of 
gene transcription. In contrast, the noncanonical pathway (right), induced by certain TNF family cytokines, such 
as CD40L and lymphotoxin-β (LT-β), involves IKKα-mediated phosphorylation of p100 associated with RelB, 
which leads to partial processing of p100 and the generation of transcriptionally active p52-RelB complexes. 
IKKα activation and phosphorylation of p100 depend on NIK, which is regulated by TRAF3, TRAF2 and 
additional ubiquitin ligases. [Oeckinghaus 2011] 
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Besides targeting of proteins for proteasomal degradation, ubiquitination also fulfills several 
tasks within the NF-κB signaling pathways. On the one hand, phosphorylation of IkB-α by the 
IKK complex is followed by rapid K48-linked ubiquitination and targeting for 26S 
proteasome mediated degradation. On the other hand, a more untypical mode of ubiquitiation 
- linear ubiquitination - was shown to be involved in activation of NEMO and the IKK 
complex. Additionally, ubiquitination can be reversed by a large family of proteins termed 
deubiquitination enzymes (DUBs). These DUBs represent an emerging focus in current 
research [Liu and Chen 2011, Harhaj and Dixit 2012]. Some other still remaining questions 
concerning the variety of NF-κB family members include what the contribution of specific 
NF-κB dimers to the physiological outcome is or which genes are regulated by which dimers.  
 
b) Parkin and NF-κB signaling 
In 2007, our research group linked the E3 ubiquitin ligase Parkin for the first time to 
increased NF-κB signaling. Blocking NF-κB activation by an IκB-α repressor or inactivation 
of IKKβ was shown to impair the neuroprotective activity of Parkin. Moreover, analysis of 
Parkin mutants revealed decreased stimulation of NF-κB-dependent transcription. Thus, this 
work connected the PD-associated protein Parkin with the NF-κB pathway playing a key role 
in inflammation and immune responses [Henn 2007]. 
A few years later, we were able to deliver a more detailed insight into the role of Parkin in 
NF-κB activation. We demonstrated that Parkin is recruited to the LUBAC under stress 
conditions, which leads to enhanced linear ubiquitination of NEMO and increased canonical 
NF-κB signaling (Fig. 20). Furthermore, the regulator of mitochondrial dynamics OPA1 could 
be identified as a new target gene, whose transcription is activated by the transcription factor 
NF-κB. These findings were confirmed in Parkin-deficient models to verify the physiological 
relevance of Parkin’s antiapoptotic and neuroprotective function [Müller-Rischart 2013]. 
Before knowing the molecular mechanism how Parkin influences NF-κB signaling, this 
pathway was already discussed as a therapeutic strategy for PD, which is characterized by 
chronic inflammation. To test the relevance of drugs targeting the NF-κB pathway, specific 
inhibitors for IKKβ or IKKγ were used, which showed that degeneration of dopamine 
producing neurons was reduced by these inhibitors in several models of PD. In short, 
targeting the NF-κB pathway might serve as a useful approach for future PD treatment [Flood 
2011]. However, it has to be considered that this fundamental transcription factor targets a 
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large number of genes and physiological responses, which might lead to unwanted side 
effects.  
 
Fig. 20: Parkin confers stress protection via NEMO, NF-κB and OPA1.  Under cellular stress conditions, 
Parkin can increase the activity of LUBAC to mediate linear ubiquitination of NEMO, which in turn activates 
the IkB kinase complex. This results in activation of NF-κB, which regulates transcription of NF-κB -responsive 
genes. OPA1 as an NF-kB target links Parkin, linear ubiquitination, and NF-κB signaling to mitochondrial 
integrity. [Müller-Rischart 2013] 
 
c) Huntingtin and NF-κB signaling 
In 2010, two publications reported different effects of mutant Htt on the transcription factor 
NF-κB. In the first paper, the Finnish researchers around Korhonen found that extended 
polyQ repeats induced ER stress, which triggers the unfolded protein response (UPR) via the 
inositol-requiring enzyme-1 (IRE1). Furthermore, decreased p65 levels together with 
increased JNK signaling, cell death and calpain activation were observed in cells expressing 
mutant Huntingtin. Calpain was suggested to promote p65 degradation [Reijonen 2010]. In 
summary, the findings demonstrated a link between mutant Huntingtin and decreased NF-κB 
signaling, although the underlying mechanism and the contribution of calpain were not 
illustrated in a satisfying profoundness. 
The second publication focused on the function of wild-type Huntingtin in neuronal cells. 
Beside its neuroprotective role, the function of wild-type Htt is still poorly understood, as 
already mentioned before. Using biochemical and imaging approaches, wild-type Htt was 
found to foster the transport of activated NF-κB from dendritic spines into the nucleus, where 
the transcription factor activates gene transcription. Next, the group of Kennedy analyzed if 
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the transport of NF-κB was impaired by polyQ expansions, which was the case. To 
recapitulate the results, an inhibitory effect of mutant Huntingtin on NF-κB signaling was 
demonstrated [Marcora and Kennedy 2010]. 
Recently, a contradicting publication argued that expression of mutant Htt influences the NF-
κB pathway by an interaction with IKKγ. This interaction led to enhanced degradation of IκB 
and enhanced nuclear translocation of p65, which was supported by transcriptional 
upregulation of intracellular immune factors. Application of glucan-encapsulated small 
interfering RNA particles to lower endogenous Huntingtin levels in human HD macrophages 
decreased cytokine production and induced transcriptional alterations [Träger 2014]. Similar 
findings were reported on analyses of HD cell culture models and R6/2 HD mice: expression 
of mutant Htt exon1 resulted in activation of the NF-κB pathway via direct interaction with 
IKKγ [Khoshnan 2004, Hsiao 2013]. 
These publications on Htt and NF-κB provided first evidence suggesting a connection of HD 
and this major transcription factor of the immune response, although they do not agree in the 
manner how mutant Htt is affecting the NF-κB pathway (increase or decrease). The activation 
status of NF-κB might be one possible explanation why neurons are especially vulnerable to 
the presence of mutant Htt in comparison to non-neuronal cells: NF-κB is mostly kept in an 
inactive state in non-neuronal cells, whereas it is constitutively activated in neuronal cells by 
basal glutamergic transmission [Meffert 2003]. 
 
d) Other neurodegenerative diseases and NF-κB signaling 
In addition to HD and PD, also other neurodegenerative diseases were connected to NF-κB 
dysfunction. Researchers concentrating on amyotrophic lateral sclerosis (ALS), which is 
characterized by TDP-43 (TAR DNA-binding protein 43) inclusions, identified TDP-43 as a 
co-activator of the NF-κB subunit p65. Using an inhibitor of NF-κB activity, ALS disease 
symptoms could be deminished in TDP-43 transgenic mice. Moreover, enhanced NF-κB 
activation in familial and sporadic ALS patients was confirmed [Swarup 2011]. A subsequent 
work discovered that only NF-κB inhibition in microglia, but not in astrocytes was able to 
rescue motor neurons from cell death and extend survival of ALS mice [Frakes 2014]. 
Moreover, Progranulin (PGRN) being involved in frontotemporal lobar degeneration (FTLD) 
was found to attenuate NF-κB signaling and thereby execute its protective role [Hwang 2013, 
Zhao 2013]. 
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Very recently, a mechanistic explanation was published deciphering the possible role of NF-
κB in Alzheimer’s Disease (AD). Besides the identification of the complement protein C3 as 
a target of the transcription factor NF-κB, exposure to Aβ (Amyloid beta) was shown to 
activate NF-κB and increase the astroglial release of C3. As brain tissues from AD patients 
and APP (Amyloid precursor protein) transgenic mice also exhibit high C3 levels, the 
application of C3 receptor agonists might be therapeutically beneficial [Lian 2015]. 
The growing number of neurodegenerative diseases linked to NF-κB signaling implies that 
this pathway could display a unifying feature of the different facets of neurodegeneration. 
 
1.3.2 JNK pathway 
JNK signaling also termed SAPK (stress-activated protein kinase) pathway is another 
pathway, which is stimulated by cytokines like TNF-α. JNKs are master protein kinases that 
regulate many physiological processes including inflammatory responses, morphogenesis, cell 
proliferation, differentiation, survival and death (Fig. 21) [Bubici and Papa 2014]. These 
various cellular responses can even be antagonistic demonstrated by data showing that JNK 
activation can on the one hand lead to apoptosis and on the other hand promote proliferation. 
Important factors to determine the direction of the response comprise cell type, context of 
other regulatory factors as well as intensity and duration of the signal. For instance, transient 
JNK activation was supposed to promote cell survival, while prolonged JNK activation is 
thought to mediate apoptosis [Leppä and Bohmann 1999, Wicovsky 2007, Davies and 
Tournier 2012]. 
So far, three different JNKs have been identified: JNK1, 2 and 3. JNK1 and 2 are ubiquitously 
expressed, whereas JNK3 was mainly found in brain, testis and heart tissue. JNK belongs to 
the MAPK (mitogen-activated protein kinase) family with the two other members ERK 
(extracellular-signal-regulated kinases) and p38. The activation of JNK is achieved by dual 
phosphorylation executed by MKKs (MAPK kinase/MAPKK), which in turn are also 
activated by phosphorylation through MAPKKKs. MKK4 and MKK7 were discovered as 
activators of JNK, which were suggested to work synergistically to phosphorylate JNK 
[Davies and Tournier 2012].  
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Fig. 21: Schematic representation of JNK signaling. The JNK signaling cascade consists of a three-
component module: upstream, MAP3Ks couple signals from the cell surface to intracellular protein effectors. 
MAP3Ks phosphorylate and activate components of the MAP2K module, such as MKK4 and MKK7. These two 
kinases in turn phosphorylate and stimulate the activity of different JNK isoforms belonging to the MAPK 
module.Upon its activation, each JNK protein itself can phosphorylate specific substrates to target different 
cellular responses. [Bubici 2014] 
 
A major target of the JNK signaling pathway is the activation of the transcription factor AP-1 
(Activator protein-1). The dimeric complex AP-1 consists of subunits from the Jun, Fos or 
ATF families and its activation is achieved by phosphorylation. JNK obtained its name due to 
its ability of phosphorylating c-Jun at two sites within its N-terminal transactivation domain 
[Liu and Lin 2005]. C-Jun can form homo- or heterodimers with Fos or ATF proteins [Vogt 
2001]. Upon activation by phosphorylation, JNK translocates from the cytosol to the nucleus 
in order to phosphorylate and activate the nuclear protein c-Jun (Fig. 22). Phosphorylation 
enables c-Jun to bind to DNA and initiate target gene transcription [Nadruz 2004]. 
In addition to c-Jun, JNK can phosphorylate transcription factors like c-Fos or ATF. All of 
these transcription factors regulate the expression of several stress-responsive genes. 
Furthermore, JNK is not only able to mediate its effects by influencing gene transcription, but 
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also by direct phosphorylation of pro- and anti-apoptotic proteins like Bim or Bcl-2 [Weston 
and Davis 2002]. 
 
Fig. 22: Schematic model of acute JNK and c-Jun activation induced by various stimuli including TNF-α 
or pressure overload in the heart. Upon activation of JNK, phosphorylated JNK translocates to the nucleus and 
activates c-Jun by phosphorylation. Activated c-Jun contributes to the dimeric transcription factor AP-1 and 
results in gene transcription. [Nadruz 2004] 
 
Increased levels of JNK activation in brain homogenates of patients with different tauopathies 
provide evidence that the JNK pathway plays a critical role in the pathogenesis of various 
neurological disorders [Cui 2007]. 
It becomes also more and more apparent that persistent activation of JNKs is involved in 
cancer development and progression. Therefore, JNKs represent attractive targets for 
therapeutic intervention. However, a deeper understanding of the molecular mechanisms 
determining a pro- or anti-apoptotic outcome and the crosstalk with other pathways has to be 
gained, before new drugs can be developed into successful therapies [Bubici and Papa 2014, 
Davies and Tournier 2012]. 
 
1.3.3 Caspase pathways 
a) Apoptosis and caspases 
The TNF receptor belongs to the family of death receptors (DR) and can also initiate an 
apoptotic pathway besides NF-κB and JNK signaling. Apoptosis or programmed cell death 
(PCD) consists of a well-regulated process including activation of an enzyme cascade 
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resulting in cell death. PCD can occur as apoptosis (type I), autophagy (type II) or necrosis 
(type III) [Ouyang 2012]. 
Apoptosis includes two major pathways: the extrinsic or death receptor pathway and the 
intrinsic or mitochondrial pathway. These two pathways, mediated by different death stimuli, 
were found to influence each other and to converge on the same execution reaction [Elmore 
2007]. The central components of the apoptotic response are conserved enzymes termed 
caspases (cysteine proteases cleaving after an aspartate residue), which irreversibly commit a 
cell to die. Two categories of caspases are involved in the apoptotic process: initiator caspases 
including Caspase-2, -8, -9 and -10 versus effector caspases including Caspases-3, -6 and -7. 
To protect the cell from constant apoptotic signaling, caspases are present as catalytically 
inactive zymogens and have to undergo proteolytic activation when apoptosis is initiated 
[Riedl and Shi 2004]. 
 
b) Extrinsic and intrinsic apoptotic signaling 
The intrinsic apoptotic pathway is triggered by stress-inducing stimuli like DNA damage or 
oncogene activation. Stress-induced apoptosis results in formation of pores in the outer 
mitochondrial membrane, which is followed by the release of proteins such as cytochrome c, 
SMAC (second mitochondria-derived activator of caspase)/ DIABLO (direct inhibitor of 
apoptosis-binding protein with low pI) from the intermembrane space of mitochondria into 
the cytoplasm (Fig. 23). Mitochondrial cytochrome c release is regulated by anti-apoptotic 
(Bcl-2, Bcl-xL) and pro-apoptotic (Bax, Bak, tBid) Bcl-2 family members and activates 
Apaf1 (apoptotic protease-activating factor 1) in the cytoplasm allowing formation of the 
apoptosome, which mediates activation of the initiator Caspase-9. Finally, activation of 
Caspase-9 triggers a caspase cascade. 
Within the extrinsic pathway, death receptors like TNF-R or Fas containing an extracellular 
region and a cytoplasmic death domain (DD) bind to homotrimeric ligands like TNF-α or 
FasL. This leads to binding of FADD and Procaspase-8 forming the death-inducing signaling 
complex (DISC). This complex drives the auto-catalytic activation of Procaspase-8. Upon 
activation of Caspase-8, the execution phase of apoptosis is triggered [Riedl and Shi 2004]. 
The caspase cascade or execution phase, which unifies both the intrinsic and extrinsic 
pathway, consists of the activation of effector caspases (mainly Caspase-3 and -7), which 
cleave important cellular substrates like PARP (Poly ADP-ribose polymerase) resulting in 
biochemical and morphological changes characteristic for the apoptotic phenotype.  
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The protein Bid (BH3 interacting-domain death agonist), which is converted by Caspase-8 to 
tBid (truncated Bid), additionally connects the extrinsic to the intrinsic pathway. Interaction 
of tBid with Bax, a Bcl-2 family protein, results in cytochrome c release [Elmore 2007, 
MacFarlane and Williams 2004]. 
 
Fig. 23: The intrinsic and extrinsic pathway. The intrinsic pathway (left) is activated by stress-inducing 
stimuli resulting in mitochondrial release of proteins, such as cytochrome c. Released cytochrome c binds to 
apoptotic protease-activating factor 1 (Apaf1), which promotes formation of the apoptosome complex and 
activation of Caspase-9. The extrinsic pathway (right) is triggered by activation of death receptors such as the 
TNF receptor and results in rapid activation of Caspase-8. Both the intrinsic and extrinsic pathway share the last 
part, where the activated initiator Caspases-8 or -9 activate the effector Caspases-3, -6 and -7. These effector 
caspases are responsible for apoptosis of the cell. [MacFarlane and Williams 2004]  
 
One important regulatory mechanism of programmed cell death is the presence of IAPs 
(inhibitors of apoptosis proteins). XIAP, c-IAP, Livin and Survivin are some members, which 
belong to this protein family. So far, the best characterized one is XIAP (X-chromosome-
linked inhibitor of apoptosis), which binds Caspase-3 and -7, thereby inhibiting their 
activation and preventing apoptosis [Scott 2005]. For instance, binding of DIABLO, which is 
released from mitochondria upon induction of apoptosis, blocks XIAP activity. How the 
different IAPs inhibit apoptosis mechanistically at the molecular level is to date not 
completely understood.  
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1.3.4 Crosstalk between NF-κB, JNK and caspase pathways 
For an organism, the balancing act between cell survival and cell death is a key function. The 
elimination of dysfunctional cells like cancer cells is crucial for surviving, but too excessive 
cell death results in diseases, such as neurodegenerative diseases [Papa 2004]. One 
mechanism to regulate this decision is the crosstalk between the NF-κB, the JNK and the 
caspase signaling pathways.  
An example to illustrate the crosstalk between prosurvival NF-κB and proapoptotic caspase 
signaling can be given by RIP1 (receptor-interacting protein 1). RIPs are kinases important 
for sensing cellular stress and controlling cell death. RIP1 features a death domain, which 
mediates binding to other DD-containing receptors like the TNF receptor. It was observed that 
NF-κB activation by RIP1 can on the one hand lead to induction of antiapoptotic genes, 
whereas RIP1 overexpression can on the other hand lead to apoptosis. These seemingly 
opposing effects can be elegantly explained by formation of two distinct TNF-induced 
signaling complexes (Fig. 24): Complex I, including TRADD, RIP1 and TRAF2 promotes 
rapid NF-κB activation and gene expression of antiapoptotic factors, whereas complex II, 
composed of TRADD, RIP1, TRAF2 and additionally FADD as well as caspase-8 and -10, 
has a proapoptotic effect. In contrast to the membrane-bound complex I, complex II is located 
in the cytosol. Upon TNF-α stimulation, complex I is formed at the TNF receptor and triggers 
NF-κB activation. Within one hour, the components of complex I (TRADD, RIP1, TRAF2) 
have already been released from the receptor and bind to FADD and caspases in the cytosol 
for activation of apoptosis. This highlights the transformation of complex I to complex II as a 
central point in the decision of whether to live or to die. It remains unclear, how this 
dissociation of the complex I factors is regulated. Complex II migth only be able to trigger 
apoptosis when NF-κB is defective or inhibited [Oeckinghaus 2011]. 
Within the last decade, the Yuan lab discovered a novel regulated necrotic cell death pathway 
termed necroptosis, which also requires RIP1 and was added to the already known pathways 
via complex I and II [Degterev 2008, Degterev 2005]. Hence, complex II can exist in two 
forms: complex IIa (former complex II) and complex IIb (the newly discovered necroptotic 
complex). Complex IIb is characterized by the two additional members RIP3 and MLKL 
(mixed lineage kinase domain-like). Furthermore, necroptosis is suppressed by Caspase-
8/FADD-mediated apoptosis [Zhou and Yuan 2014]. 
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Fig. 24: TNF-R1-mediated pathways of cell survival, apoptosis and necroptosis.  Stimulation of the TNF 
receptor leads to the formation of complex I consisting of TRADD, TRAF2, RIP1, and cIAP1 located at the 
cellular membrane. Polyubiquitination of RIP1 by cIAP1, fosters the recruitment of the IKK complex activating 
the NF-κB survival pathway. In the absence of cIAP1 or cFLIP, a switch takes place and RIP1, FADD and 
Caspase-8 form the cytosolic complex IIa to activate the caspase cascade and induce apoptosis. When Caspase-8 
activity is inhibited, RIP1 interacts with RIP3 and MLKL to form complex IIb which is involved in mediation of 
necroptosis. RIP3 and MLKL are phosphorylated in complex IIb and translocate to the plasma membrane, where 
the complex mediates membrane permeabilization. [Zhou and Yuan 2014] 
 
Recently, a connection of TNF signaling and the LUBAC was described. Several groups 
demonstrated that deficiency in one of the LUBAC components HOIP or Sharpin results in 
increased TNF-R1-mediated cell death. As HOIP is the catalytically important component of 
the LUBAC, HOIP deficiency leads to aberrant complex-IIa formation upon TNF stimulation 
mediating apoptosis instead of survival. These findings confirm the importance of the 
LUBAC to prevent cells from TNF-induced cell death by maintenance of complex I action 
[Peltzer 2014, Kumari 2014, Rickard 2014]. 
An additional interplay occurs between the NF-κB and JNK pathway. NF-κB provides its 
survival signals via inhibiton of JNK. Experiments in NF-κB-deficient cells showed an 
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impaired downregulation of JNK signaling [Papa 2009]. Moreover, analysis of these NF-κB-
deficient cells treated with JNK inhibitors or silenced for MKK7 expression revealed a rescue 
from TNF-α induced cell death, which points to a proapoptotic role of JNK. Another 
paradigm for the crosstalk of NF-κB and JNK signaling has been discussed during the 
inflammatory response. There, TNF-α activates NF-κB signaling and JNK signaling can be 
suppressed by either upregulation of Gadd45β (Growth arrest DNA damage-inducible gene 
45 β), XIAP or other factors, which hinder JNK activation. Gadd45β binds to the JNK kinase 
MKK7 and thereby blocks its activity (Fig. 25) [Papa 2004]. 
 
 
 
Fig. 25: Crosstalk between TNF-R-induced pathways. Formation of complex I leads to NF-kB activation, 
Gadd45b induction, JNK inhibition and cell survival (left). Alternatively, formation of complex II leads to 
Caspase-8/10-mediated cleavage of Bid, which then induces cytochrome c release from mitochondria and cell 
death (right). The scheme also depicts JNK activation, which promotes programmed cell death by triggering 
release of Smac/Diablo into the cytosol, inhibiting the TRAF2-IAP1 complex and consequently activating 
Caspase-8. Moreover, the Gadd45b-MKK7 interaction linking the JNK and NF-kB pathways is shown. [Papa 
2004]  
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Interestingly, a JNK substrate, which fosters TNF-α induced apoptosis, was missing for a long 
time. In 2006, it was reported that JNK activation by TNF-α leads to reduced levels of an NF-
κB-induced antiapoptotic protein termed c-FLIP inhibiting Caspase-8. The underlying 
mechanism involves phosphorylation and activation of the E3 ligase Itch by JNK; Itch in turn 
ubiquitinates c-FLIP to promote its degradation via the proteasome [Chang 2006]. In 
conclusion, several players participating in the crosstalk of NF-κB and JNK signaling could 
be identified so far underpinning the importance of this counterregulation. 
 
 
2. Aim of the thesis 
Recently, our group demonstrated that the PD-associated protein Parkin can influence the 
NF-κB pathway through increased activation of the LUBAC [Müller-Rischart 2013]. In the 
past few years, mutant Huntingtin and HD were also linked to NF-κB signaling by a few 
publications [Reijonen 2010, Marcora 2010, Hsiao 2013, Träger 2014]. However, these 
reports were inconsistent and argued either for decreased or increased activation of the NF-κB 
pathway caused by mutant Huntingtin. In addition, a common convincing molecular 
mechanism how mutant Huntingtin leads to the monitored effects on this TNF-α mediated 
pathway was missing. Furthermore, it is still unclear, how such an interference in NF-κB 
signaling or its consequences can serve as an explanation for the observed mitochondrial 
alterations and the death of neurons in HD. 
 
To minimize or clear these ambiguities, I focused on the following questions within the 
project: 
 
 Confirm and clarify effect of Huntingtin on NF-κB signaling (up- or downregulation) 
 Identify step of the NF-κB pathway, which is affected by mutant Huntingtin 
 Investigate if other TNF-mediated pathways (JNK and caspase signaling) are also 
influenced by the presence of polyQ aggregates 
 Analyze if dysregulation of pathways can explain impact of mutant Huntingtin on 
mitochondrial function and apoptotis 
 Investigate if Parkin or HOIP can rescue from altered TNF signaling caused by mutant 
Huntingtin 
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3. Results 
NF-κB is a key transcription factor that regulates expression of genes involved in cell 
survival, differentiation and proliferation [Hayden 2012]. After having discovered a 
connection between the PD-associated protein Parkin and the NF-κB signaling pathway 
[Müller-Rischart 2013], we were interested in identifying a possible link between the HD-
associated protein Huntingtin and the transcription factor NF-κB. 
For Parkin, we had observed that it can increase the activity of the LUBAC in response to 
cellular stress (Fig. 26). The LUBAC mediates linear ubiquitination of NEMO resulting in 
activation of the IKK complex. The IKK complex in turn activates NF-κB by phosphorylation 
and subsequent degradation of the inhibitory protein IκB-α, so that the NF-κB heterodimer 
(p50-p65) can translocate to the nucleus and regulate transcription of NF-κB responsive genes 
like OPA1.  
 
Fig. 26: Parkin exerts its stress protective function via activation of LUBAC, NEMO, NF-κB and OPA1.  
[Graphical abstract, Müller-Rischart 2013].  
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In the following, the knockdown of Parkin in human neuroblastoma SH-SY5Y cells serves as 
an example to demonstrate the effect of Parkin expression levels on NF-κB activation. To 
monitor NF-κB activation, we focused on one of the last steps of the NF-κB signaling 
pathway – the translocation of the activated NF-κB-heterodimer from the cytosol to the 
nucleus. For analysis via indirect immunofluorescence, we concentrated on the subunit p65. 
Upon stimulation with TNF-α, p65 is normally imported into the nucleus in control cells, 
whereas p65 is still mainly localized in the cytosol of Parkin-deficient cells (Fig. 27). This 
finding supports the functional relevance of endogenous Parkin within the NF-κB pathway. 
 
Fig. 27: Nuclear translocation of p65 is decreased in SH-SY5Y cells silenced for Parkin expression.  
Left: p65 translocation was analyzed by indirect immunofluorescence of cells transfected with control or Parkin 
siRNA and treated with TNF-α (15 min, 20 ng/ml). Right: Quantifications are based on four independent 
experiments performed in duplicate (n ≥ 2,500). Data represent the mean ± SEM. *p ≤0.05; **p ≤0.01; ***p 
≤0.001. [Müller-Rischart 2013] 
 
3.1 NF-κB signaling is impaired by mutant Huntingtin 
3.1.1 Nuclear translocation of p65 is impaired in cells with polyQ aggregates 
Having seen that nuclear translocation of p65 is a convenient tool for monitoring NF-κB 
activation, we also applied it to study a possible effect of Huntingtin aggregates on the NF-κB 
signaling pathway. SH-SY5Y cells were transfected with myc-tagged Htt-Q20 and -Q96 for 
transient expression of wild-type and mutant Huntingtin. After treatment with TNF-α to 
induce NF-κB activation, the cells were fixed and stained against p65. 
For quantification, the following three categories were defined: full p65 translocation (p65 is 
mostly localized in the nucleus and hardly detected in the cytosol), partial p65 translocation 
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(staining intensity for p65 in the nucleus is equal to the cytosol), no p65 translocation (p65 is 
mainly located in the cytosol and hardly detected in the nucleus). Full p65 translocation was 
observed in 100% of the cells expressing Q20, while only 7 % of the cells expressing Q96 
showed full translocation (Fig. 28). Approximately 50 % of transfected cells with aggregates 
showed no p65 translocation at all. 
  
Fig. 28: Nuclear translocation of p65 is decreased in SH-SY5Y cells expressing polyQ aggregates.  Left: 
p65 translocation was analyzed by indirect immunofluorescence of cells transfected with control (Q20) or 
mutant (Q96) myc-tagged Huntingtin treated with TNF-α (15 min, 20 ng/ml). Right: Quantifications are based 
on three independent experiments performed in triplicates (n ≥ 1,000). Data represent the mean ± SEM. 
Statistical analysis was first performed separately for each subgroup and the total p-value was determined by the 
mean value of the single statistical results. *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
 
   
Fig. 29: Nuclear translocation of p65 is decreased in inducible N2a cells expressing polyQ aggregates. Left: 
p65 translocation was analyzed in induced N2a-cells expressing polyQ aggregates upon TNF-α treatment (30 
min, 20 ng/ml) and induction with Muristerone A for 72 h. Induced cells express GFP. Right: Quantifications are 
based on three independent experiments performed in triplicates (n ≥ 1,000). Data represent the mean ± SEM. *p 
≤0.05; **p ≤0.01; ***p ≤0.001. 
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Similarly, inducible murine neuroblastoma N2a cells were analyzed (Fig. 29). Upon induction 
with Muristerone A, these inducible cell lines express a fusion protein consisting of N-
terminal Huntingtin fragments with different polyQ stretches (Q16, Q150) and EGFP as a 
reporter protein. 59 % of the Q16-expressing cells showed full translocation in comparison to 
none of the Q150-expressing cells. Overall, the lowered p65 translocation in the N2a cells 
confirmed the previous finding in SY-SY5Y cells that NF-κB activation is impaired in cells 
displaying cytosolic Huntingtin aggregates. 
 
3.1.2 Phosphorylation and degradation of IκB-α is reduced in cells with polyQ 
aggregates 
It was not clear from the obtained data, whether polyQ aggregates directly block NF-κB 
translocation or an impairment of the NF-κB pathway occurs already at an earlier step 
upstream of the translocation. Therefore, we next investigated the phosphorylation and 
degradation of IκB-α located upstream of NF-κB translocation. Within the NF-κB pathway, 
binding of TNF-α to its receptor leads to activation of the IKK complex, which is followed by 
phosphorylation and degradation of the inhibitory protein IκB-α. Thereby, the transcription 
factor NF-κB is liberated and can translocate to the nucleus to activate gene transcription.  
 
 
Fig. 30: N2a-Q150 cells show reduced phosphorylation (upper panel) and impaired degradation of IκB-α 
(lower panel) in comparison to control N2a-Q16 cells upon TNF-α treatment. Cells were treated with TNF-α 
for 0-240 min (upper panel) and 0-30 min (lower panel). p-IκB-α, IκB-α and GAPDH as control were analyzed 
by western blotting. 
 
Analysis of phospho- IκB-α and IκB-α protein levels after treatment of induced N2a cells with 
TNF-α revealed that both steps – phosphorylation and degradation of IκB-α – were 
significantly impaired in cells expressing Q150 (Fig. 30). Furthermore, it should be noted that 
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the IκB-α protein seems to be expressed at higher levels even in untreated cells, which points 
to the possibility that the defect in NF-κB signaling caused by polyQ aggregates occurs 
already upstream of the IκB-α degradation.  
 
3.2 Impaired NF-κB signaling occurs due to sequestration of LUBAC E3 ligases 
3.2.1 LUBAC components show increased aggregation upon co-expression of 
polyQ aggregates  
The higher basal IκB-α levels in N2a-Q150 cells supported the assumption that the 
impairment in NF-κB signaling occurs at an early step of the pathway. Knowing from recent 
studies that the PD-associated protein Parkin intervenes at one of the top steps of NF-κB 
signaling to increase activity of the LUBAC and thereby NF-κB activation, we were 
wondering if the Huntingtin aggregates might also interfere with LUBAC activation [Müller-
Rischart 2013]. One possibility would be that polyQ aggregates sequester and trap 
components of the LUBAC. To test this hypothesis, we first performed filter trap assays to 
analyze protein aggregation. For filter trap assays, the cell lysate is soaked through a cellulose 
acetate membrane (pore size 0.2 µm), which cannot be passed by large protein aggregates. 
The aggregates are trapped at the membrane and can be detected via Western Blotting. In our 
assays, HEK293T cells were transfected with myc-tagged Htt-Q20, -Q96 or in combination 
with either Parkin, HOIP or HHARI-HA as control.  
  
 
Fig. 31: Aggregation of Parkin and HOIP but not HHARI is increased when Htt-Q96 is co-expressed. 
Filter trap assays of HEK293T cells transfected with Htt-Q20 or Q96 and Parkin, HOIP or HHARI-HA.  
 
Analysis of the different Htt constructs produced only detectable aggregates, when Htt-Q96 
was expressed and not -Q20 (Fig. 31). For Parkin (both endogenous as well as 
overexpressed), aggregation was significantly increased in the presence of Q96 and a strong 
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increase of HOIP aggregation was also detected when Q96 was co-expressed (only seen for 
overexpressed HOIP). HHARI was analyzed as control protein, as it is an RBR E3 ubiquitin 
ligase similar to Parkin and HOIP that was so far not associated with the LUBAC. 
Aggregation of HHARI was not altered by Q96 co-expression. 
To confirm the co-aggregation of mutant Huntingtin with other LUBAC components, HOIL-
1L and SHARPIN were also examined. These filter trap assays showed similar findings as an 
increased signal for HOIL-1 L or SHARPIN was only detected when Q96 was co-expressed 
(Fig. 32). 
 
Fig. 32: Aggregation of HOIL-1L and SHARPIN is increased when Htt-Q96 is co-expressed. Filter trap 
assays of HEK293T cells transfected with Htt-Q20 or Q96 and HOIL-1l or SHARPIN. 
 
3.2.2 LUBAC components co-localize with polyQ aggregates 
For further clarification of the implied sequestration caused by the presence of polyQ 
aggregates, confocal microscopy was performed. In SH-SY5Y cells overexpressing mutant 
Htt, Parkin and HOIP were clearly enriched at the region of the aggregates (Fig. 33). In 
contrast, the RBR E3 ubiquitin ligase HHARI was equally distributed within the cytosol. 
Similarly to HOIP and Parkin, HOIL-1L was co-localizing with polyQ aggregates, whereas 
co-localization between SHARPIN and the aggregates was weaker and did not result in 
cytosolic depletion. These findings confirmed the data from the filter trap assays and the 
hypothesis that mutant Huntingtin sequesters LUBAC components. As a consequence, the 
LUBAC E3 ligases might not be able anymore to fulfill their functions including promotion 
of NF-κB signaling. 
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Fig. 33: Parkin, HOIP, HOIL-1L and SHARPIN co-localize with polyQ aggregates, while HHARI is still 
distributed equally within the cytosol. SH-SY5Y cells were co-transfected with the indicated constructs and 
analyzed via indirect immunofluorescence. 
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3.3 Wild-type Parkin or HOIP can rescue from impaired NF-κB signaling 
3.3.1 Impaired p65 translocation in SH-SY5Y cells can be rescued by wild-type 
Parkin or HOIP 
If sequestration of Parkin and other LUBAC components by Huntingtin aggregates is the 
reason for impaired NF-κB signaling, overexpression of these proteins should result in a 
rescue of the defective pathway. To test this hypothesis, p65 translocation was used as a first 
read-out. SH-SY5Y cells were transfected with Htt-Q96 in combination with wild-type or 
mutant Parkin or HOIP. Co-expression of both wild-type Parkin and HOIP significantly 
decreased the number of cells impaired in p65 translocation (Fig. 34). Besides this, neither the 
catalytically inactive mutants of Parkin (C431F) or HOIP (C885A, C885S) nor the pathogenic 
loss-of-function Parkin mutants (∆UBL, G430D) could revert the impairment in p65 
translocation. 
 
 
 
Fig. 34: Impaired p65 translocation in SH-SY5Y cells expressing mutant Huntingtin can be rescued by 
overexpression of wild-type but not mutant Parkin or HOIP  TNF-α treatment was conducted for 15 min 
with a concentration of 20 ng/ml. Data represent the mean ± SEM of at least three independent experiments, 
each performed in triplicate. n ≥ 1,000 induced or transfected cells were assessed per condition. Statistical 
analysis was first performed separately for each subgroup and the total p-value was determined by the mean 
value of the single statistical results. *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
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3.3.2 Impaired p65 translocation in neurons can be rescued by wild-type Parkin 
or HOIP 
Moreover, the confirmation of this observation in a more disease-relevant model was of 
interest. Therefore, nuclear p65 translocation was additionally analyzed in primary 
hippocampal neurons, which were transfected with Htt-Q20 or -Q96 in combination with 
wild-type Parkin or HOIP. Both TNF-α as well as IL-1β, another NF-κB activator, were used 
as stimulators for p65 translocation. As the translocation efficiency of p65 was slightly higher 
with IL-1β, this stimulus was applied in the rescue experiments with co-expression of Parkin 
or HOIP (Fig. 35). While approximately 84 % of the Q96-expressing neurons showed no p65 
translocation, co-expression of Parkin or HOIP reduced this number to 44 and 50 %, 
respectively. However, this rescue was only partial as no cells with full p65 translocation 
could be discovered like in cells expressing the control construct Htt-Q20. Taken together, co-
expression of wild-type Parkin or HOIP was able to rescue p65 translocation in immortalized 
cells as well as in primary neurons.  
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Fig. 35: Nuclear translocation of p65 is decreased in hippocampal neurons expressing polyQ aggregates, 
which can be increased by co-expression of wild-type Parkin or HOIP.  
Neurons were transfected with Q20 or Q96 together with Parkin or HOIP and treated with TNF-α (60 min, 20 
ng/ml) or IL-1β (30 min, 10 ng/ml) before fixation. Data represent the mean ± SEM of at least three independent 
experiments, each performed in triplicate. n ≥ 100 cells were assessed per condition. Statistical analysis was first 
performed separately for each subgroup and the total p-value was determined by the mean value of the single 
statistical results. *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
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3.3.3 Impaired NF-κB activity in inducible N2a cells can be rescued by wild-
type Parkin or HOIP 
NF-κB luciferase reporter assays with the inducible N2a cells (Q16, Q150) and stimulation 
with TNF-α provided further evidence for the rescue properties of Parkin or HOIP regarding 
defective NF-κB signaling due to the presence of mutant Huntingtin (Fig. 36). TNF-α 
treatment induced an almost 3-fold increase of NF-κB activity in Q16 control cells. In Q150 
N2a cells expressing polyQ aggregates, this increase was dramatically reduced to 1.3-fold. 
However, transient expression of wild-type Parkin or HOIP increased NF-κB-dependent 
transcription to approximately 3-fold, which was comparable to control cells. The two 
catalytically inactive mutants Parkin C431F and HOIP C885S did not significantly increase 
the levels of induction in Q150 cells. In conclusion, several experiments have so far supported 
the potential of wild-type Parkin or HOIP to overcome the NF-κB impairment caused by 
polyQ aggregates.  
 
 
Fig. 36: Wild-type Parkin or HOIP can restore impaired NF-κB activity.  Induced N2a cells (Q16 and 
Q150) were transfected with an NF-κB luciferase reporter and control, Parkin or HOIP construct. After TNF-α 
treatment for 16 h (10 ng/ml) luciferase activity in cell lysates was determined. Data represent the mean ± SEM 
of at least three independent experiments, each performed in triplicate. *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
 
3.4 Mutant Huntingtin causes mitochondrial alterations 
3.4.1 Mutant Huntingtin provokes increased mitochondrial fragmentation in 
inducible N2a cells 
As mitochondrial alterations have already been described in several models of polyQ diseases 
[Scorrano 2012], we next investigated mitochondrial morphology upon overexpression of Htt 
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aggregates. As we could not observe any severe effects of transient overexpression of Htt-
Q96 on the mitochondrial fragmentation in SH-SY5Y cells (data not shown), we moved on to 
the inducible N2a cells, which are stably overexpressing Htt with different polyQ lengths. 
Indeed, we found that Htt-Q16 control cells showed less than 5 % of cells with fragmented 
mitochondria in comparison to 56 % of the Htt-Q150 cells (Fig. 37).  
 
 
 
Fig. 37: Induced Q150-N2a cells show increased mitochondrial fragmentation.  Upper panel: The cells were 
stained with TOM20 to visualize mitochondria. Cells displaying an intact network of mitochondria were 
classified as non-fragmented, while cells with a disrupted mitochondrial network were classified as fragmented. 
Lower panel: Quantifications are based on three independent experiments performed in triplicates (n ≥ 1,000). 
Data represent the mean ± SEM. *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
 
3.4.2 Increased mitochondrial fragmentation in neurons can be rescued by 
Parkin or HOIP 
A similar increase in mitochondrial fragmentation was seen in primary hippocampal neurons 
(from 12 % in Q20- to 62 % in Q96-expressing neurons). Here, we tested if overexpression of 
wild-type Parkin or HOIP influences the mitochondrial phenotype in Q96-expressing cells. 
Strikingly, mitochondrial fragmentation observed upon Q96-overexpression was in fact 
significantly alleviated in neurons co-expressing either Parkin or HOIP (Fig. 38).  
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Fig. 38: Hippocampal neurons expressing polyQ aggregates show an impaired mitochondrial network. A 
tubular mitochondrial network can be restored by co-expression of Parkin or HOIP. The neurons were 
transfected with Q20 or Q96 together with wild-type Parkin or HOIP. Cells displaying an intact network of 
tubular mitochondria were classified as non-fragmented. When this network was disrupted and mitochondria 
appeared predominantly spherical or rod-like the cells were classified as fragmented. Quantifications are based 
on three independent experiments performed in triplicates (n ≥ 100). Data represent the mean ± SEM. *p ≤0.05; 
**p ≤0.01; ***p ≤0.001.  
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3.4.3 Cells expressing mutant Huntingtin lack OPA1 upregulation 
In our recent work focusing on Parkin and its effect on NF-κB signaling, we identified OPA1 
as an NF-κB target gene [Müller-Rischart 2013]. OPA1 is a mitochondrial GTPase and an 
essential regulator of structural and functional mitochondrial integrity. For this reason, we 
were asking the question if NF-κB-mediated expression of OPA1 is altered in cells expressing 
mutant Huntingtin, as we have already observed changes in mitochondrial morphology in 
these cells. To answer this question, we analyzed expression levels of mitochondrial proteins 
in induced N2a cells after stimulation with TNF-α.  
     
 
 
Fig. 39: Defective OPA1 protein upregulation is observed in Q150 cells upon TNF-α treatment (upper 
panel, left). OPA1 upregulation can be reconstituted by viral overexpression of wild-type Parkin in Q150 
cells (upper panel, right). Other mitochondrial marker proteins such as TIM44 are also slightly decreased in 
Q150 cells. Upon TNF-α treatment (10 ng/ml) for the indicated hours, expression levels of mitochondrial 
proteins and the loading control GAPDH were analyzed by western blotting. Lower panel: Quantification of 
mitochondrial protein levels in Q16 and Q150 cells upon TNF-α treatment. Protein levels are normalized to 
GAPDH and quantification is based on three independent experiments. Quantification of protein levels upon 
viral overexpression of Parkin was not possible due to insufficient repetitions of the experiment. Data represent 
the mean ± SEM. *p ≤0.05; **p ≤0.01; ***p ≤0.001.  
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Similar to previous observations in other cell lines such as SH-SY5Y or MEF cells [Müller-
Rischart 2013], OPA1 was upregulated in control Htt-Q16 N2a cells upon treatment with 
TNF-α, while another mitochondrial protein, TIM44, was not changed significantly in its 
expression pattern (Fig. 39). Interestingly, in cells expressing mutant Htt, this upregulation of 
OPA1 was completely abolished and even a slight decrease of OPA1 protein levels was 
observed. Furthermore, the expression level of the other mitochondrial marker protein was 
also decreased in these cells expressing aggregates suggesting a decrease in mitochondrial 
biogenesis in polyQ-expressing cells, as has been reported previously [Scorrano EMBO 
2012].  
Through viral transduction and overexpression of wild-type Parkin, OPA1 protein levels 
could be elevated in Q150 cells, which were treated with TNF-α (Fig. 39, upper panel, right).  
 
3.5 PolyQ aggregates induce increased JNK and caspase signaling 
3.5.1 Phosphorylation of c-Jun is increased in hippocampal neurons expressing 
polyQ aggregates 
TNF-α is a proinflammatory cytokine signaling both cell survival as well as cell death 
(Wajant 2003). The biological outcome of TNFα treatment is determined by the balance 
between NF-κB and Jun kinase (JNK) signaling: NF-κB promotes survival, whereas JNK can 
enhance cell death (Chang 2006). Typically, activation of NF-κB results in inhibition of 
Caspase-8 and suppresses pro-apoptotic signaling via JNK. As our data show that TNF-α 
induced pro-survival NF-κB activation is blocked in cells expressing mutant Huntingtin, the 
balance might be shifted towards pro-apoptotic signaling in these cells. To test this 
hypothesis, we focused on the phosphorylation of c-Jun, which was identified as the essential 
substrate of JNK signaling to regulate stress-induced apoptosis [Behrens 1999].  
Primary hippocampal neurons were transfected with polyQ constructs and nuclear 
phosphorylated c-Jun was analyzed by indirect immunofluorescence. Surprisingly, we found a 
significant increase in c-Jun phosphorylation in Q96-expressing neurons (67 % compared to 
8 % in Q20-expressing neurons) even without TNFα-stimulation (Fig. 40). Beyond that, co-
expression of wild-type Parkin or HOIP was able to reduce the number of phospho-c-Jun-
positive cells significantly to 29 % and 13 % when Huntingtin aggregates were present. 
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Fig. 40: Phosphorylation of c-Jun is increased in hippocampal neurons expressing Q96 aggregates. Upper 
panel: Overexpression of Htt-Q96 results in increased phosphorylation of c-Jun, while co-expression of Parkin 
or HOIP decreases the number of phospho-c-Jun positive cells. Cells displaying strong nuclear p-cJun staining 
were classified as phosphorylation-positive, while cells with no or weak staining in the nucleus were classified as 
phosphorylation-negative. Lower panel: Quantifications are based on three independent experiments performed 
in triplicates (n ≥ 100). Data represent the mean ± SEM. *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
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3.5.2 Parkin reduces increased phosphorylation of c-Jun in N2a cells with polyQ 
aggregates 
When the analog experiment was performed in inducible N2a cells (Fig. 41), similar numbers 
were obtained for cells showing phosphorylated c-Jun in control Htt-Q16 cells (17 %) versus 
mutant Htt-Q150 cells (72 %).  
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Fig. 41: In induced N2a cells with Q150 aggregates phosphorylation of c-Jun is increased. Overexpression 
of Parkin decreases the number of phospho-c-Jun positive cells. Quantifications are based on three 
independent experiments performed in triplicates (n ≥ 300). Data represent the mean ± SEM. *p ≤0.05; **p 
≤0.01; ***p ≤0.001. 
 
It should be noted that overexpression of Parkin or HOIP in these induced cells had to be 
verified by additional immunofluorescence staining of the transfected cells and visualizing 
them in a third channel (Fig. 41, lower panels, blue). Unexpectedly, only overexpression of 
Parkin could lower the level of c-Jun-phosphorylation. The failure of the HOIP rescue in this 
case might be explained by the quantitative sequestration of most HOIP molecules through 
the aggregates at this expression level. As seen in the immunofluorescence images, 
overexpressed Parkin shows mostly equal distribution within the cytosol, while HOIP seems 
to be enriched around the aggregates. Overall, the DNA amount used for transfection is 
supposed to determine if there is still free Parkin or HOIP available, which is not sequestered 
by mutant Huntingtin and can still activate NF-κB and block JNK signaling.  
 
3.5.3 JNK and caspase signaling are elevated in N2a cells expressing polyQ 
aggregates 
In addition to indirect immunofluorescence analysis of phosphorylated c-Jun, we examined 
expression levels of different markers for JNK and caspase activation by western blotting to 
prove the increased apoptotic signaling in cells overexpressing Htt aggregates (Fig. 42).  
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Fig. 42: Induced Q150-N2a cells show elevated levels of JNK and caspase activation upon TNF-α 
treatment. For JNK activation, phosphorylated c-Jun and phosphorylated JNK were analyzed; for caspase 
activation, cleaved Caspase-3 and cleaved PARP were investigated.  
 
After the phosporylation of JNK, p-JNK translocates to the nucleus and phosporylates c-Jun 
which then serves as transcription factor. Both, p-JNK and p-c-Jun were found to be increased 
in Q150-N2a cells upon TNF-α treatment. Besides this, elevated caspase activation in cells 
expressing mutant Huntingtin could be demonstrated by increased levels of cleaved Caspase-
3 and cleaved PARP. 
 
3.6 Toxicity of polyQ aggregates is amplified in Parkin- or HOIP-deficient cells 
As overexpression of Parkin or HOIP was able to reverse the impairment induced by polyQ 
aggregates on NF-κB signaling (e.g. nuclear translocation of p65), we wanted to test if 
silencing of Parkin or HOIP in cells expressing mutant Huntingtin would lead to a further 
increase in polyQ toxicity. SH-SY5Y cells expressing Htt-Q96 showed a marked increase in 
phosphorylation of c-Jun, which was used as an indicator for JNK signaling, and additional 
silencing of Parkin or HOIP expression in these cells by RNA interference led to an additional 
increase in c-Jun phosphorylation (Fig. 43). When Parkin or HOIP was reintroduced in the 
silenced cells, the level of phosphorylated c-Jun could be significantly lowered.  
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In conclusion, these data confirm that both endogenous Parkin as well as HOIP reduce polyQ-
mediated toxicity, while silencing of these two E3 ubiquitin ligases leads to intensified JNK 
signaling in cells with Huntingtin aggregates. 
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Fig. 43: Phosphorylation of c-Jun is increased in SH-SY5Y cells expressing Htt-Q96 aggregates. 
Moreover, knockdown of Parkin or HOIP leads to an additional increase in the number of phospho-c-Jun 
positive cells, whereas reintroduction of Parkin or HOIP decreases the number of phospho-c-Jun positive 
cells. 24 h after knockdown, cells were transfected with the indicated constructs and fixed 72 h after transfection. 
Data represent the mean ± SEM of at least three independent experiments, each performed in triplicate. n ≥ 300 
transfected cells were assessed per condition. *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
 
 
3.7 Sequestration of LUBAC components in brain sections from a HD patient 
3.7.1 Huntingtin antibody 1HU-4C8 detects cytosolic Huntingtin aggregates 
To validate if our data from immortalized and primary cells pointing to a sequestration of 
LUBAC components by Htt aggregates, can also be seen in human patient brains, we 
collaborated with the two neuropathologists Dr. Thomas Arzberger and Dr. Kohji Mori.  
First, we had to establish the staining of Huntingtin aggregates in brain sections. In the 
beginning, the well-established antibody mEM48 was used for detection. However, as this 
antibody stains only nuclear aggregates (Fig. 44) and our focus lies on cytosolic ones, another 
antibody had to be selected. Surprisingly, the main focus of HD research is concentrated on 
nuclear aggregates although wild-type Htt is known to be localized in the cytosol and it is 
rarely studied how wild-type cytosolic Htt can develop into a nuclear aggregate.  
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After intensive search in the long list of available Huntingtin antibodies, 1HU-4C8 was 
identified as a potential candidate for staining of cytosolic aggregates in paraffin-embedded 
sections, as this antibody was raised against an immunogen containing a bigger C-terminal 
part than the mEM48 antibody (Table 2). 
 
 
Fig. 44: DAB (Diaminobenzidine) staining of Huntingtin aggregates in control (left) and HD patient brains 
(right) with the antibodies mEM48 (above) and 1HU-4C8 (below). While the mEM48 antibody detects 
mostly nuclear aggregates, the 1HU-4C8 antibody shows mainly cytosolic aggregates on HD patient tissue. Both 
antibodies show cytoplasmic staining in the control tissue. 
 
 
mEM48 
GST fusion protein from the first 256 amino acids from human Htt with the 
deletion of the polyglutamine tract 
1HU-4C8 Htt fragment from amino acids 181 to 810 as a fusion protein 
 
Table 2: Immunogen species of Huntingtin antibodies mEM48 and 1HU-4C8. (www.emdmillipore.com)  
 
DAB staining with 1HU-4C8 showed normal cytosolic distribution of wild-type Htt in control 
cases and indeed enabled us to detect cytosolic aggregates in HD patient brain tissue (Fig. 
44). These rare cytosolic aggregates found in HD brain were mostly located in close 
proximity to the nucleus and an additional thin ring structure could sometimes be observed 
around the nucleus. Interestingly, we detected cytosolic aggregates with this antibody only in 
brain sections from patient 1, while staining of patient 2 brain did not result in any positive 
signal for cytosolic Huntingtin aggregates. As patient 1 was characterized with pronounced 
atrophy of the Nucleus caudatus (late stage) and patient 2 showed almost no atrophy of the 
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Nucleus caudatus (early stage), this was a surprising finding (Table 3). Initially, we had 
assumed that cytosolic aggregates might appear with higher frequency only in earlier and not 
advanced HD cases. This question will be adressed with further experiments on different HD 
cases representing different stages of the disease and different brain regions including the 
striatum. 
 
HD patient 1 male, 57 years, pronounced atrophy of the Nucleus caudatus (late stage) 
HD patient 2 male, 74 years, little atrophy of the Nucleus caudatus (early stage) 
 
Table 3: Clinical data of HD patients 1 and 2. 
 
3.7.2 Cytosolic Huntingtin aggregates co-localize with LUBAC element HOIP 
Next, another important question was addressed: Do cytosolic aggregates in HD patient brains 
co-localize with LUBAC components? For answering this crucial question, immuno-
histochemistry staining with antibodies against Parkin and HOIP was established first (Fig. 
45).  
 
 
Fig. 45: DAB staining of PRK8/ Parkin (left) and HOIP (right) antibody in control brains. 
 
Co-staining of Htt and HOIP revealing a co-localization of these two proteins supports the 
notion that LUBAC components are sequestered by Huntingtin aggregates in HD patient brain 
(Fig. 46). 
Unfortunately, a convincing co-staining of Parkin (PRK8) and the 1HU-4C8 could not be 
performed as the antibodies 1HU-4C8 and PRK8 are derived from the same species (mouse) 
and therefore did not yield a suitable signal in co-staining experiments.  
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Fig. 46: Immunofluorescence staining of Huntingtin aggregates and HOIP in HD patient brain indicates 
co-localization. 
 
Nuclear Htt aggregates are reported to be positive for the ubiquitin-binding scaffold protein 
p62, which colocalizes with ubiquitinated protein aggregates. Therefore, we also tested if the 
cytosolic aggregates we detected with the 1HU-4C8 antibody, co-localize with this 
degradation marker. Indeed, we found that the cytosolic Htt aggregates observed in HD 
patient brain were positive for p62 (Fig. 47). 
 
 
Fig. 47: Immunofluorescence staining of Huntingtin aggregates and p62 in HD patient brain shows co-
localization. 
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To summarize, the obtained results give insight into the impact of mutant Htt on the NF-κB 
signaling pathway. Cytosolic polyQ aggregates sequester and trap several LUBAC 
components involved in the activation of the IKK complex. Without activation of the IKK 
complex, phosphorylation and degradation of the inhibitor protein IκB-α are blocked. Further 
downstream, nuclear translocation of p65 and activation of gene transcription are also 
lowered leading to defective OPA1 upregulation and increased mitochondrial fragmentation. 
TNF-α stimulation causes either a pro-survival response via NF-κB or a pro-apoptotic 
response via long-lasting JNK signaling and the caspase cascade. As the cell-protective 
pathway is blocked by the Huntingtin aggregates, destructive JNK and caspase signaling are 
activated instead (Fig. 48). Importantly, overexpression of wild-type E3 ubiquitin ligases 
Parkin and HOIP can at least partially restore impaired NF-κB signaling and protect cells 
from programmed cell death, as demonstrated by several approaches. This switch from NF-
κB-mediated survival to apoptosis signaling might be of special relevance to neurons and 
thereby explain the increased vulnerability of this cell population to an impairment in NF-κB 
signaling by polyQ aggregates.  
 
Fig. 48: When the pro-survival NF-κB pathway is blocked by sequestration of LUBAC components 
through Huntingtin aggregates, JNK and complex IIa-mediated apoptotic signaling are activated instead 
and promote programmed cell death [modified from graphical abstract, Müller-Rischart 2013]. 
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4. Discussion 
4.1 Role of LUBAC in prevention of programmed cell death 
Expansion of the polyQ stretch in the Huntingtin gene leads to severe impairments in 
mitochondrial integrity and neuronal survival. In this work, an interplay of cytosolic 
Huntingtin aggregates with components of the LUBAC was identified resulting in a switch 
from pro-survival NF-κB signaling to pro-apoptotic JNK and caspase signaling within a cell. 
Previously, the E3 ubiquitin ligase Parkin was shown to increase LUBAC activation, whereas 
HOIP was found to be the catalytic subunit of the LUBAC [Müller-Rischart 2013, Smit 
2012]. Therefore, we addressed the question, if Parkin and HOIP can rescue from defective 
NF-κB signaling in cells expressing Huntingtin aggregates. Our experiments demonstrate that 
overexpression of either Parkin or HOIP was able to alleviate the impact of mutant Huntingtin 
not only on NF-κB activation measured by p65 translocation or luciferase reporter assays but 
also on mitochondrial morphology and on JNK activation. But it is still unclear, how this 
rescue effect of Parkin or HOIP on impaired NF-κB signaling caused by Huntingtin 
aggregates can be explained on a mechanistic level. One possible explanation would be that 
these components of the LUBAC might be able to revert aggregate formation and could be 
involved in dissolving of polyQ aggregates. However, we could not confirm this hypothesis 
by any experimental evidence, as the number and size of Htt aggregates was not altered by co-
expression of Parkin or HOIP - at least not at the time points and in the cell types we looked 
at. 
The more plausible explanation is that overexpression of these mediators of the NF-κB 
pathway restores cytosolic protein levels, which can perpetuate the signaling and lead to a 
prosurvival response. Most of the endogenously available Parkin and HOIP is probably 
sequestered by mutant Huntingtin aggregates and therefore not sufficient unbound protein is 
available anymore for downstream signaling to activate NF-κB and protect the cell from 
apoptosis. This idea is supported by the observation that experiments with low levels of 
overexpressed HOIP, for instance, show mainly a ring-like staining around the aggregates and 
cytosolic depletion for HOIP when co-expressed with Htt-Q150. Expression of higher 
amounts of HOIP results in a mostly equal cytosolic distribution of the LUBAC component 
and only a slightly increased staining intensity around the aggregates compared to the cytosol. 
During the last few years, the LUBAC and its different components have increasingly gained 
importance, as their contribution to the NF-κB pathway was shown to be crucial. Despite the 
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remaining uncertainty regarding the exact complex composition and the detailed role of 
Parkin or Sharpin, it is beyond all question that this complex plays a major part in cell 
protection. Therefore, its functional efficiency and capability are essential for inhibition of 
programmed cell death. Very recently, three publications focusing on HOIP and Sharpin 
reported that HOIP- or Sharpin-deficient cells show increased TNF-R1 mediated cell death. 
Furthermore, it was demonstrated that Sharpin can prevent TNF-R1 mediated cell death 
[Kumari 2014, Peltzer 2014, Rickard 2014]. Taken together, these findings underline the 
significance of the LUBAC in the context of complex I mediated survival signals versus 
complex II mediated death signals, as the LUBAC maintains complex I mediated signaling to 
prevent switching to the cell death program via complex IIa. 
 
4.2 Huntingtin aggregates 
Huntingtin aggregates were found to be present in brains of R6/2 mice as well as human HD 
brains and, in addition, showed positive for ubiquitin staining [Davies 1997, DiFiglia 1997]. 
Both, the length of the polyQ stretch and the length and amount of Huntingtin fragments 
determine the aggregation process of mutant Huntingtin. It was demonstrated by biochemical 
analyses that nuclear and cytosolic aggregates are made of different components: While 
nuclear aggregates consist mainly of N-terminal Huntingtin fragments, extranuclear 
inclusions are composed of full-length and fragmented Huntingtin. A model termed the toxic 
fragment hypothesis, argues that toxic Huntingtin fragments are liberated by proteolytic 
cleavage. These fragments contain the expanded polyQ stretch and their accumulation might 
promote activation of caspases and programmed cell death. Experiments on cleavage 
processes and existence of N-terminal Huntingtin fragments evidenced that both normal and 
mutant Huntingtin undergo cleavages. However, it was shown that mutant Huntingtin is more 
susceptible to proteolysis [Zuccato 2010]. 
It is still an issue of intensive debate, which of the species is the most toxic form within these 
aggregation pathways. Are small monomers or oligomers more toxic than large fibers or 
aggregates themselves or is it the other way around? And, is toxicity of the aggregates 
dependent on the cellular compartment? Previously, it was assumed that nuclear Huntingtin 
aggregates are particularly toxic and that they sequester and block transcription factors and 
regulators in the nucleus [Yang 2002]. However, current views favor the hypothesis that 
Huntingtin inclusions are a protective mechanism of cells by sequestering toxic factors 
[Bennett 2007]. Preliminary data from our group on the translocation of p65 in cells 
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expressing mutant Htt showed that impaired NF-κB activation was already seen at time 
points, when Htt was not yet in an aggregated state. However, the impairment was not as 
pronounced as in cells where the aggregates had already formed. These findings point to toxic 
features of both soluble and insoluble cytosolic mutant Huntingtin species, which could be 
prevented by inclusion of these species together with their removal and transport into the 
nucleus. In this work, we focused on cytosolic aggregates as wild-type Huntingtin is known to 
be localized in the cytoplasm and our aim was to investigate early cellular changes occurring 
due to aggregate formation. At present, mainly nuclear Huntingtin aggregates are examined, 
because of their numerous appearance in post mortem HD brains. Although it is a great 
challenge to find less abundant cytosolic aggregates in advanced stages of the disease, it will 
be essential to tackle this problem for a better understanding of HD. In the future, it would 
therefore be important to concentrate also on early cytosolic aggregation steps within 
Huntingtin research and clarify the identity of the pathogenic species as well as the 
mechanism of how cytosolic soluble Huntingtin can turn into a nuclear insoluble aggregate. 
 
4.3 Selectivity of neurodegeneration 
Our observations demonstrate that the presence of mutant Huntingtin results in a clear switch 
from prosurvival signaling via NF-κB to proapoptotic cellular signaling, which explains the 
caspase-induced death of affected cells. However, this finding of increased cell death upon 
exposure to polyQ aggregates cannot explain why a selective degeneration of a particular 
neuronal population occurs. It is known that affected brain regions in Alzheimer’s Disease are 
involved in memory, while affected brain regions in PD and HD are responsible for motor 
function. Furthermore, degeneration in PD is mainly seen in dopaminergic neurons of the 
substantia nigra, whereas degeneration in HD hits mostly striatal GABAergic neurons.  
Several possibilities are discussed how specific neuronal loss could be explained. Proteostasis 
is one of the major factors suggested to play a role in this context. As neurons are postmitotic 
cells, they require consistent maintenance of their protein quality and rely on a functional 
proteostasis machinery [Margulis and Finkbeiner 2014, Saxena and Caroni 2011]. Formerly, 
Huntingtin aggregates were thought to block the proteasome in HD [Bence 2001]. This was 
emended by findings implying that mutant Huntingtin indirectly affects the proteasome by 
impairment of the chaperone system leading to increased load of misfolded proteins that 
finally overburden the ubiquitin proteasome system (UPS) [Hipp 2012]. Lower activity of the 
UPS in the striatum was recently reported, suggesting the necessity of functional capability of 
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the striatal UPS [Tsvetkov 2013]. Another argument supporting this hypothesis is based on 
the regional selectivity of inclusion body (IB) formation. IBs are only detected in particular 
brain regions although mutant Huntingtin is ubiquitously expressed [Margulis and Finkbeiner 
2014].  
The activation status of NF-κB might be another feasible explanation why neurons are 
especially vulnerable to the presence of mutant Huntingtin in comparison to non-neuronal 
cells: In non-neuronal cells, NF-κB is mostly kept in an inactive state, while being 
constitutively activated by basal glutamatergic transmission in neuronal cells [Meffert 2003]. 
This permanent activation of the NF-κB pathway, which is blocked by Huntingtin aggregates 
according to our results, would followingly be converted into permanent apoptotic signaling 
finally leading to programmed cell death.  
In 2009, the protein Rhes (Ras homolog enriched in striatum), which is selectively enriched in 
the striatum, was identified as an interaction partner of mutant Huntingtin. It was reported that 
Rhes induces sumoylation of mutant Huntingtin and thereby causing cytotoxicity. For this 
reason, Rhes and its interaction with Huntingtin was used as further possible explanation for 
the specific striatal neurodegeneration seen in HD [Subramaniam 2009]. Though, in vivo data 
confirming this interaction are still missing. 
Despite all attempts of explanation, the selective vulnerability of specific brain regions 
remains one of the most intruiging mysteries in neurodegenerative disease research and a 
better understanding of the underlying mechanisms is necessary for the development of 
targeted therapeutic interventions [Jackson 2014]. 
 
4.4 Cellular defects caused by mutant Huntingtin 
Apparently, the cellular effects of mutant Huntingtin are complex and comprise impaired 
gene transcription, cytoplasmic sequestration of important factors, insufficient protein folding, 
impairment of the UPS as well as increased cell death and mitochondrial dysfunction (Fig. 
49). Mutant Huntingtin could either inhibit transcription factors by aggregate formation in the 
nucleus or sequester transcription factors in the cytoplasm and block their translocation into 
the nucleus. For instance, CBP (CREB binding protein) and TBP (TATA box binding protein) 
were detected in intranuclear polyQ aggregates. Furthermore, chaperones, ubiquitin and 
proteasome subunits accumulate in Huntingtin aggregates, which points to an involvement of 
the UPS machinery [Landles and Bates 2004, Costa and Scorrano 2012].  
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Fig. 49: Model for cellular pathogenesis in HD. (1, 2, 4) An HD mutation causes abnormal folding of 
Huntingtin, which should be corrected by chaperones or cleared by proteasomal degradation. (3) Alternatively, 
mutant Huntingtin might also undergo proteolytic cleavage producing N-terminal fragments. In the cytoplasm, 
mutant Huntingtin might impair the proteasomal function directly or indirectly, which leads to accumulation of 
misfolded proteins. (5) Aggregation and sequestration of other proteins in the cytoplasm could lead to 
mitochondrial damage. (6) To protect itself, the cell presumably incorporates toxic proteins into cytoplasmic 
perinuclear aggregates. (7) An additional protection mechanism is assumed to comprehend the translocation of 
mutant Huntingtin into the nucleus, where nuclear inclusions may block gene transcription. [Landles and Bates 
2004] 
 
Our data especially emphasize both mitochondrial fragmentation and dysregulation as well as 
increased cell death signaling caused by the presence of Htt aggregates. Decreased p65 
translocation, reduced OPA1 protein levels and increased levels of JNK signaling 
(phosphorylated c-Jun and JNK) and the caspase pathway (Caspase-3 and PARP) in cells 
containing polyQ aggregates are clear indicators for a switch from NF-κB-mediated signaling 
to complex IIa-induced apoptosis. How the other observed cellular defects such as hindered 
protein degradation by the proteasome can be integrated into the dysregulation of these 
pathways, has to be adressed in future projects. In addition, it should be investigated and 
distinguished what the primary and what the secondary effects of aggregated Huntingtin are. 
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4.5 Balanced crosstalk of pathways 
In general, an essential function of a cell is the decision about living or dying. Therefore, the 
underlying signaling pathways have to be well-regulated and adjusted to the respective 
circumstances. While the prosurvival pathway via the transcription factor NF-κB should 
predominantly be active in cells, the proapoptotic pathways including JNK and caspase 
signaling should be repressed to ensure a proper immune response to inflammatory stimuli. 
Only when cells are irreparably damaged, the program should be switched from the pro-
survival to the pro-apoptotic channel through suppression of canonical NF-κB signal 
transduction and activation of the JNK and the caspase cascade. 
As described before, mutant Htt was found to influence the NF-κB pathway directly by 
sequestration of LUBAC components and thereby to affect the JNK and the caspase pathways 
indirectly, as suppression of NF-κB signaling is accompanied by elevated cell death signaling. 
Our findings focusing on Huntingtin and HD, taken together with earlier reports on other 
diseases such as liver diseases indicate that the balance between activation and repression of 
the investigated pathways as well as the functional crosstalk between these pathways is 
crucial for the cellular fate.  
Few mediators and mechanisms of the crosstalk could be discovered so far: On the one hand, 
NF-κB activation blunts JNK activation by inducing JNK inhibitory proteins such as XIAP 
and controling the levels of reactive oxygen species (ROS). [Papa 2009, Wullaert 2006]. On 
the other hand, Siva was found to interact with XIAP thereby shifting the balance from NF-
κB-mediated prosurvival signaling to proapoptotic JNK and Caspase-3 signaling [Resch 
2009]. These mediators between the pathways might be interesting targets for therapeutic 
interventions.  
One of the main future challenges will be the identification of further balance regulating 
mechanisms within this pathway network. In particular, targeting and tackling of these 
regulators to overcome deficient signaling caused by multiple factors including protein 
aggregates like in HD will be important. In the end, the interplay of NF-κB, JNK and caspase 
signaling determines the cellular response to TNF-α stimulation (Fig. 50). 
The most fascinating current question is whether the imbalanced pathway network observed 
in HD models might also be involved in other neurodegenerative diseases and serve as a 
general concept to explain the mitochondrial alterations as well as effects on viability seen in 
most neurodegenerative diseases. For Parkin and PD, the link to the LUBAC and NF-κB 
signaling was already demonstrated. This indicates the importance of common pathways for 
Discussion 
73 
 
the development of at least HD and PD and tempts one to speculate that other cytosolic 
aggregates occurring in different diseases could also sequester and trap components of the 
NF-κB pathway such as the LUBAC. Thereby, the increased vulnerability of neurons under 
stress conditions might be explained, as the aggregates induce a switch from an anti- to a pro-
apoptotic cellular response. 
 
 
 
Fig. 50: Sensitive balance between pro-survival and pro-apoptotic signaling.  Activation of the NF-κB 
pathway and suppression of JNK and caspase signaling lead to a pro-survival outcome, while inhibition of NF-
κB signaling connected with increased activation of the JNK and caspase pathway promotes programmed cell 
death [modified from Resch 2009]. 
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5. Methods 
5.1 Cell culture 
5.1.1 Cultivation 
Both immortal as well as primary cell lines were cultivated as adherent monolayers in either 
25 cm
2
 or 75 cm
2
 tissue culture flasks at 37°C and 5% CO2. Every 3 – 4 days, the cells were 
splitted by washing once with PBS (Phosphate Buffered Saline), trypsination at 37°C, 
inhibition of trypsin by fresh FCS-containing medium and transfer of a cell aliquot into a new 
flask with fresh medium for further cultivation. All cell lines, the appropriate media and 
splitting ratios are listed in the following table (table 3). 
 
Cell line type medium splitting ratio 
SH-SY5Y Human neuroblastoma DMEM F-12 + 15% FCS 
+ 1% NEAA (+1% PS) 
1:6 – 1:12 
HEK 293T Human embryonic kidney DMEM GlutaMax  
+ 10% FCS (+1% PS) 
1:10 – 1:20 
N2a Htt-Q16/  
N2a Htt-Q150 
Murine neuroblastoma 
DMEM + 10% FCS  
+ 2 mM L-Glutamine  
+ 0.1 mg/ml G418  
+ 0.1 mg/ml Zeocin  
(+1% PS) 
1:5 – 1:20 
 
Table 4: Cell lines and cultivation details. 
 
5.1.2 Plating 
For transfections or treatments, cells were counted and plated in the desired confluency in 
different cell culture dish types (table 4). 
 
Cell line experiment dish density 
SH-SY5Y WB 6-well plate 3-5 x 10
5
 
 IF 6-well plate 1-1,75 x 10
5
 
HEK 293T WB 6-well plate 1 x 10
6
 
HEK 293T LUC 12-well plate 4 x 10
5
 
HEK 293T Filter trap 12-well plate 1,5 x 10
5
 
HEK 293T Lin Ubi assay 10 cm culture dish 2 x 10
6
 
N2a  IF 12-well plate 1 x 10
5
 
N2a WB 6-well 5 x 10
5
 
 
Table 5: Plating details of cell lines for different experiments. WB = Western Blot, IF = 
immunofluorescence, LUC = Luciferase assay, Lin Ubi Assay = Linear ubiquitination assay. 
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5.1.3 Preparation and cultivation of mouse or rat primary neurons 
Cortices of mouse embryos (E14 - 15) were isolated and treated with Papain for 15 – 20 
minutes (min) at 37°C to digest the tissue. After removing the Papain solution, cells were 
dissociated by mild trituration with a 2 ml pipette and plated onto Poly-L-Lysine-coated 
dishes. For immunofluorescene experiments, 4 x 10
5 
cells were seeded on coverslips in 12-
well-plates (DMEM + 10% FCS + 1% PS). The medium was switched to neuronal medium 
(Neurobasal + 5 mM HEPES + 0.5 mM L-Glutamine + 2% B27 supplement + 1% PS) after 3 
to 4 hours. One week after preparation, fresh medium was added to the cultured neuronal 
cells. 
Further rat cortical and hippocampal neurons were kindly provided by Dieter Edbauer’s 
group. These neurons were prepared at stage E19 and cultivated in Neuronal Basal Medium 
supplemented with SM1 Neuronal Supplement, L-Glutamine and PS.  
 
5.1.4 Transient transfection 
First, transient transfection for overexpression of genes was mainly performed 24 h after 
plating or 24 to 48 hours after a knockdown. DNA (0.2 - 1 µg per 6-well) was mixed with 
Plus reagent in Opti-MEM, while Lipofectamine reagent was added to Opti-MEM in a 
separate tube (for details see table 5). The separate mixes were incubated for 15 min at room 
temperature (RT), merged and incubated for another 15 min at RT. Before the transfection 
mix was dripped onto the cells, the medium was switched to Opti-MEM. After 3 to 5 hours of 
incubation, normal growth medium was added. Cells were harvested 24 to 72 hours after 
transfection for analysis. 
 
Cell line ratio Plus: Lipo 
SH-SY5Y 8:6 
HEK 293T, N2a 6:8 
 
Table 6: Ratio of transfection reagents for different cell lines. Specifications are valid for cells plated in 6-
well-format. Lipo = Lipofectamine. 
 
Second, transfection of small interfering RNA (siRNA) was used to silence the expression of 
specific genes. These transfections were performed as reverse transfections together with the 
plating of the cells. For this purpose, siRNA for the specific gene was incubated together with 
5 µl of the transfection reagent RNAimax and Opti-MEM in 6-well plates for15 min at RT 
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(for details see table 6). A negative control duplex siRNA with medium GC-content served as 
control. In the meantime, cells were trypsinated and counted, before they were plated in an 
appropriate density in the 6-well plates containing the siRNA transfection mix. After 5 to 24 
hours, normal growth medium was added to the cells. 
 
Gene volume siRNA 
Parkin 5 µl (stock solution 20 µM) si1 or si2 
HOIP 6 ul (stock solutions 20 µM) si1+2+3 (1:1:1) 
 
Table 7: Optimized siRNA composition for specific genes. Specifications are valid for SY-SY5Y and HEK 
293T cells. 
 
Third, transfection of neurons was mostly performed on day 12 post preparation and the cells 
were harvested on day 3 or 4 post transfection. Neuronal experiments were mainly conducted 
in 12-well plates with neurons seeded on glass coverslips for immunofluorescence analyses. 
For the transfection, 2 separate mixes (1.8 µg DNA in Neurobasal and 3.3 µl Lipofectamine 
2000 in Neurobasal per 12-well) were made separately, mixed and incubated at RT for 30 
min. Meanwhile, a new 12-well plate was prepared with incubation medium (Neurobasal + 
PS + Glutamine), the neurons on coverslips were washed with warm Neurobasal medium and 
transfered to the new 12-well plate for transfection. The old plate was kept warm in the 
incubator. Then, transfection followed by dripping the transfection mix onto the cells and 
incubation at 37°C for 45 min. Afterwards, the coverslips were washed twice with Neurobasal 
medium and transfered back into the original plate, where they stayed for 72 to 96 hours until 
their harvest. 
 
5.1.5 Lentiviral transduction 
N2a cells were transduced with lentiviruses for stable overexpression of either wild-type 
Parkin or a control vector as lentiviral transduction allows higher transfection efficiencies 
compared to transient transfection of plasmid DNA with Lipofectamine and Plus. Generation 
of the lentiviral expression vector Fu-∆Zeo-ParkinWT and purification of the lentiviruses was 
kindly performed by Anna Pilsl [Müller-Rischart 2013].  
 
5.1.6 Induction of stable N2a cell lines 
The ecdysone-inducible mammalian expression system from Invitrogen was used for stable 
expression of a Huntingtin fragment (90 amino acids from exon1 of a HD patient) combined 
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with different polyQ lengths and the reporter protein GFP (green fluorescent protein). We 
tested the N2a cell lines expressing a polyQ stretch of 16 or 150. Different ecdysone analogs 
can be used to induce this expression system, among them the herbal steroids Muristerone A 
and Ponasterone A. For induction, we used 1 µM Muristerone A and for differentiation of the 
N2a cells, 2.5 - 5 mM dbcAMP (Dibutyryl cyclic adenosine monophosphate, (N6,2'-O-
dibutyryl)-adenosine-3',5'-mono-phosphate) were applied in differentiation and induction 
medium (DMEM + 1%FCS + 2mM L-Glutamine + 0.1 mg/ml G418 + 0.1 mg/ml Zeocin +1% 
PS). The cells were mainly treated for 72 to 96 hours, as sufficient aggregate production was 
observed at these time points in the case of N2a Htt-Q150 cells. 
 
5.1.7 Treatment of cells 
To stimulate TNF receptor-mediated signaling pathways, the cytokines TNF-α or IL-1β were 
utilized. TNF-α was applied at a concentration of 10 - 20 ng/ml, while IL-1β was applied at a 
concentration of 10 ng/ml.  
 
5.2 Protein biochemistry 
5.2.1 Cell harvest and lysate preparation 
For harvesting, cells were washed twice with PBS on ice and scraped off the plates with a cell 
scraper. Next, they were transfered to an Eppendorf tube and centrifuged for 5 min at 5000 
rpm and 4°C. The cell pellet was either stored at -20°/ -80°C or subsequently lysed. 
Lysis conditions depended on the carried out experiment, but a detergent buffer containing 
0.5 - 1 % Triton X-100 in PBS (+ protease inhibitor cocktail) was mainly used for cell lysis. 
The lysate was incubated for 5 min on ice. For some experiments such as a Parkin 
knockdown, the complete lysate was used and needled, while for most other experiments an 
additional centrifugation step of 15 min at 13000 rpm and 4°C followed to pellet the cell 
debris. The supernatant was then transfered to a new tube and only this soluble fraction was 
used for analysis. 
To prepare samples for Western Blot analysis, protein concentration of the cell lysates was 
measured by BCA protein assay, Laemmli sample buffer (+β Mercaptoethanol) was added to 
the lysate and the samples were incubated for 10 min at 95°C. Then, the samples were either 
analyzed after the boiling step or stored at -20°C until further usage. 
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5.2.2 SDS PAGE 
Sodium dodecylsulphate polyacrylamide gelelectrophoresis (SDS-PAGE) under denaturing 
conditions was used for separation of proteins according to their molecular weight. Equal 
amounts of protein (5 - 20 ug per sample) were loaded onto 10 - 15% separation gels 
depending on the size of the considered proteins. The electrophoresis gels ran on the minigel 
system from BIORAD at a constant current of 25 mA per gel for 90 to 120 min. 
 
5.2.3 Western Blot 
After the electrophoresis step, the separated proteins were transfered from the gel onto a 
PVDF (polyvinylidene difluoride) membrane by applicaton of the same minigel system from 
BIORAD and 400 mA for 1 hour. To block unspecific binding, the membranes were 
incubated in 5% milk in TBS-T at RT after the protein blotting, before the membrane was 
transfered to a tube containing the respective primary antibody in milk solution. Incubation at 
4°C overnight or for 1 hour at RT followed. Next, three washing steps with TBS-T were 
performed and the second antibody, which was conjugated to the enzyme HRP (horseradish 
peroxidase), was added to the membrane. Finally, three washing steps and detection of the 
antigen via an enhanced chemoluminescence (ECL) reaction and exposure to an X-ray film 
was conducted.  
 
5.2.4 Filter trap assay 
To analyze protein aggregates, filter trap assays were performed. As aggregates are bigger in 
size and cannot pass through a membrane with a pore size of 0.2 µm, they are retained when 
the cell lysate is soaked through the membrane, while non-aggregated proteins can easily slip 
through the membrane. Afterwards, the retained aggregates can be detected via antibodies and 
chemoluminescence similar to the last part of Western Blotting. 
For this assay, a different lysis buffer was used, which additionally contained DNase (lysis 
buffer: 1% Triton X-100 + 15 mM MgCl2 + 0.2 mg/ml DNase in PBS). Cells were lysed and 
ultracentrifuged at 55 000 rpm and 4°C for 30 min. Next, the pellet was resuspended in SDS-
buffer (2% SDS in100 mM Tris pH 7) and incubated for 1hour at RT. When the incubation 
was finished and the pellet dissolved, the slot-blot equipment containing the activated 
cellulose acetate membrane was assembled. The samples were diluted 1:5 in three steps, 
loaded in four lanes (undiluted, 1:5, 1:25, 1:125) into the slots and soaked through the 
membrane by application of a vacuum. After three washing steps with PBS, the membrane 
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was removed from the slot blot chamber and blocked with milk solution. The antibody 
detection worked as described in the previous chapter (see “Western Blot”). 
 
5.2.5 Linear ubiquitination assay 
The linear ubiquination assay served to detect proteins, which were pulled down by 
recombinant Strep-tagged UBAN domain from the cell lysate and visualized with a ubiquitin 
antibody. As the UBAN domain, which is part of the IKK subunit NEMO, binds to linear 
ubiquitin chains, it can be used to pull down proteins with linear ubiquitin chains. 
Transfections of large quantities for linear ubiquitination assays were performed with calcium 
phosphate, because this method is more cost-saving than transfection with Lipofectamine and 
Plus reagent. For this purpose, DNA was mixed with CaCl2 and HeBs buffer (50 mM HEPES, 
280 mM NaCl, 1.5 mM Na2HPO4) and incubated for 15 min at RT. In the following step, the 
transfection mix was dripped onto the cells in 10 cm dishes. After 16 h of incubation, fresh 
medium was added to the cells. 
Upon harvest, lysis of the cells included resuspension in a denaturing buffer (1% SDS in 
PBS), incubation for 10 min at 95°C and needling for sufficient dissolving. Then, the lysate 
was diluted 1:10 with 1% Triton X-100 in PBS and centrifuged for 15 min at 4600 rpm and 
4°C. The supernatant was transfered to a new tube for subsequent co-immunoprecipitation 
(Co-IP) and a small aliquot was taken as input control. 
For the Co-IP, recombinant UBAN protein was added to the cleared lysate and the samples 
were incubated with mild swinging overnight at 4°C. On the following day, Strep Tactin 
Sepharose beads were used to bind the Strep-tag attached to the UBAN domain. After 3 to 4 
hours of incubation at mild swinging and 4°C, a centrifugation step for 5 min at 1500 rpm and 
4°C pelleted the beads together with the bound complexes of the UBAN domain and linear 
ubiquitinated proteins. Several washing steps of the beads followed. Finally, addition of 
Laemmli sample buffer (+β Mercaptoethanol) and an incubation step for 10 min at 95°C led 
to the dissociation of the bound protein complexes from the beads. Input controls and 
supernatants of the pulldown samples were loaded onto SDS gels and Western Blot analysis 
was conducted. For the detection of ubiquitinated proteins, a nitrocellulose membrane was 
used and boiled after the blotting step for 5 min, before the first antibody was added.  
This linear ubiquitination assay was performed both with HEK cells transiently expressing 
polyQ aggregates as well as inducible Htt-expressing N2a cells, but all experiments revealed 
indefinite results regarding a possible effect of Htt aggregates on linear ubiquitination levels. 
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5.2.6 Luciferase reporter assay 
Luciferase reporter assays are based on the expression of the reporter gene luciferase, which is 
combined with promoter sequences or transcription factor binding sites to be considered. In 
our case, several NF-κB binding sites were put in front of the luciferase gene. Upon binding 
of NF-κB to the respective responsive elements, transcription of the reporter gene is activated 
and luciferase protein is produced. The resulting protein converts the substrate luciferin into 
oxyluciferin accompanied with the production of light, which can be measured by a 
luminometer. 
 
Fig. 51: Bioluminescent reaction catalyzed by firefly luciferase. [Promega] 
 
Cells were co-transfected with the NF-κB reporter construct and other plasmids to be 
analyzed. Transfected cells were harvested and resuspended in reporter lysis buffer (provided 
by the Luciferase Assay System, Promega). After incubation for 5 min on ice and vortexing, 
the samples were centrifuged for 15 min at 13000 rpm and 4°C. The supernatant was used for 
luminometric measurements and the obtained raw values were normalized to protein 
concentration. 
 
5.2.7 ATP assay 
To determine the ATP content of cells, the same principle as described for luciferase reporter 
assays was applied: the luciferase reaction produces light, which can be quantified.  
24 hours prior to the cell harvest, the culture medium was replaced with low Glucose medium 
(3 mM Glucose) to induce a metabolic shift from glycolysis to mitochondrial respiration for 
ATP production. Furthermore, control cells were treated with 10 µM CCCP three hours 
before the harvest. For the measurement, cells were scraped off the plates, resuspended 
carefully in PBS and lysed in the cell lysis buffer of the ATP Bioluminescence Assay Kit HS 
II (Roche). After 5 min of incubation at RT, the lysates were centrifuged for 1 min at 10000 
rpm and 4°C. The supernatant was used for luminometric measurement and the obtained raw 
values were normalized to protein concentration. 
ATP assays were performed with inducible Htt-expressing N2a cells. However, the obtained 
results did not yield a clear effect of Huntingtin aggregates on ATP levels. 
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5.2.8 Immunofluorescence of cultured cells 
Immunofluorescence stainings of cultured cells can be used for different assays such as 
nuclear translocation of p65, assessment of mitochondrial morphology via staining of 
mitochondrial proteins such as TOM20, phosphorylation of c-Jun or activation of Caspase-3. 
The cells were washed with PBS and fixed with 3.7% Formaldehyde in PBS for 15 min at 
RT. Then, 0.1% Triton X-100 in PBS was applied for 10 min to permeabilize the cell 
membranes. For blocking of unspecific binding, the coverslips were transfered to a humid 
chamber and covered with blocking buffer (5% horse serum, 0.1% Tween20 in PBS). There, 
the coverslips were incubated for 2 hours at RT. In the following, the first antibody was added 
to the samples and incubation of 1 hour at RT was sufficient, before several washing steps 
with PBS and PBS-T were performed. Further incubation with the secondary antibody was 
conducted for 1 hour at RT and the coverslips were finally mounted with DAPI-containing 
mounting medium onto slides.  
Quantification of cells and capturing of the images was done either at the fluorescence 
microscope Axio Imager A2 or the confocal microscope LSM 710. 
 
5.2.9 Immunofluorescence of human sections 
Immunofluorescence as well as immunohistochemistry experiments with paraffin-embeded 
sections were kindly performed by Dr. Kohji Mori. All patient materials were generously 
provided by Dr. Thomas Arzberger from the Neurobiobank Munich, Ludwig-Maximilians-
University (LMU) Munich and were collected and distributed according to the guidelines of 
the local ethical committee. 
First, the sections were deparaffinized with xylene and ethanol treatment and briefly washed 
with deionized water. After antigen retrieval through microwaving in 100 mM citrate buffer 
pH 6.0 and blocking with 2% FBS, the primary antibody was added and incubation at 4°C 
overnight followed. Washing with 0.02 % Brij35 or 0.05% Tween20 in PBS and incubation 
with the secondary Alexa-conjugated antibody were the next steps. For staining of the 
nucleus, either TO-PRO-3 or DAPI were used. Confocal images were taken with the confocal 
microscopes LSM510 or LSM710. 
 
5.2.10 Immunohistochemistry of human sections 
Similar to immunofluorescence experiments with patient sections, the sections were first 
deparaffinized with xylene and ethanol treatment and briefly washed with deionized water. 
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Upon antigen retrieval through microwaving in 100 mM citrate buffer pH 6.0 and blocking of 
endogenous peroxidase with 5% H2O2 in methanol, sections were put in PBS with 0.02% 
Brij35. Blocking with 2% FBS in PBS for 5 min followed and the respective primary 
antibody was applied for 1.5 h at RT or overnight at 4°C. Next, the secondary antibody was 
applied for 1 h. After rinsing with 0.02 % Brij35 in PBS, antibody binding was detected and 
enhanced by DCS Super Vision 2 HRP-Polymer-Kit or NovoLink DS Polymer Detection 
Systems using the chromogen DAB. Counterstaining for cellular structures was performed 
with haematoxylin. Microscopic images were obtained with a BX50 microscope and Cell-D 
software (Olympus). 
 
5.2.11 Statistics 
Data represent the mean ± SEM (standard error of the mean). The student’s t-test or ANOVA 
were applied to calculate p-values for statistical analysis. P-values were assigned as listed in 
the following: *p ≤0.05; **p ≤0.01; ***p ≤0.001. 
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6. Material 
6.1 Cell culture 
6.1.1 Material 
a) Cell lines 
Cell line Type Origin 
SH-SY5Y Human neuroblastoma DMSZ, ACC-209 
HEK 293T Human embryonic kidney ATCC, CRL-1573 
N2a Htt-Q16/  
N2a Htt-Q150 
Murine neuroblastoma Ulrich Hartl 
 
b) Media 
Medium Company 
DMEM Biochrom 
DMEM GlutaMax Invitrogen 
DMEM F12 Invitrogen 
HBSS Invitrogen 
Neurobasal Invitrogen 
Neuronal basal medium Stemcell technologies 
Opti-MEM Invitrogen 
 
c) Supplements 
Supplement Company 
B27 supplement Invitrogen 
FCS (fetal calf serum) Invitrogen 
G418/ Geneticin Invitrogen 
Glucose Invitrogen 
L-Glutamine Invitrogen 
NEAA (non-essential amino acids) Invitrogen 
PS (Penicillin/ Streptomycin) Invitrogen 
SM1 Neuronal supplement Stemcell technologies 
Zeocin Invitrogen 
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d) Transfection reagents 
Tranfection reagent Company 
Lipofectamine Invitrogen 
Plus Invitrogen 
Lipofectamine 2000 Invitrogen 
RNAiMAX Invitrogen 
 
e) siRNAs 
Target Product number Company 
Parkin 
HSS107593 (si1), 
HSS107594 (si2) 
Invitrogen 
HOIP 
HSS123836 (si1), 
HSS123837 (si2), 
HSS182838 (si3) 
Invitrogen 
Negative control 45-2001 Invitrogen 
 
f) Plasmids 
Plasmid Features Origin 
GFP pcDNA3.1 Anna Pilsl 
HOIP wt pcDNA3.1 Kathrin Müller-Rischart 
HA-HOIP pcDNA3.1 Kathrin Müller-Rischart 
HOIP C885A pcDNA3.1 Maria Patra 
HOIP C885S pcDNA3.1 Maria Patra 
HOIL-1L pcDNA3.1 Kathrin Müller-Rischart 
HOIL-1L-HA pcDNA3.1 Kathrin Müller-Rischart 
HA-HHARI pCMV Julia Schlehe 
Myc-Htt-Q20 pcDNA3.1 Ulrich Hartl 
Myc-Htt-Q96 pcDNA3.1 Ulrich Hartl 
NF-κB LUC pGL3-LUC Daniel Krappmann 
LUC pGL3-LUC Promega 
Parkin wt pcDNA3.1 Winklhofer et al, 2003 
Parkin ∆UBL pcDNA3.1 Julia Schlehe 
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Parkin C431F pcDNA Richard Youle 
Parkin G430D pcDNA3.1 Iris Henn 
Parkin W453X pcDNA3.1 Iris Henn 
Sharpin-HA pcDNA3 Anna Pilsl 
 
g) Chemicals and enzymes 
Reagents Company 
CCCP Sigma Aldrich 
dbcAMP Sigma Aldrich 
IL-1β R&D Systems 
Muristerone A Sigma Aldrich 
Papain Sigma Aldrich 
Poly-L-Lysine Sigma Aldrich 
TNF-α Biomol 
Trypsin-EDTA Sigma Aldrich 
 
h) Equipment 
Product Company 
Cell counter chamber Neubauer Labor Optik 
Cell culture dishes Nunc 
Cell culture flasks Nunc 
Cell scraper Corning Inc. 
Centrifuge Multifuge 3 S-R Heraeus 
Centrifuge for Eppendorf tubes Eppendorf 
Incubator Heraeus 
 
6.1.2 Solutions and buffers 
PBS (Phosphate buffered saline): 
3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl pH 7.4 
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6.2 Protein biochemistry 
6.2.1 Material 
a) Antibodies 
Primary antibody Company Product nr. Applic. Dilution Species 
Active Caspase 3 Cell Signaling 9664L IF 
WB 
1:250 
1:1000 
rabbit 
β-Actin Sigma Aldrich A5316 WB 1:5000 mouse 
GAPDH Life Technolog. AM4300 WB 1:4000 mouse 
GFP Roche 11814460001 WB  mouse 
HA 1.1 Covance MMS-101P IF 
WB 
1:100 
1:2000 
mouse 
HHARI/ ARIH1 (B-2) Santa Cruz Biot.  Sc-390763 IHC 1:50 mouse 
HOIL-1L (E2) Santa Cruz Biot. Sc-365523 WB 1:1000 mouse 
HOIP Acris AP16062PU-N IF 1:500 goat 
HOIP Sigma Aldrich Sab2102031 IF 
WB 
IHC 
1:500 
1:1000 
1:50-200 
rabbit 
Hsp60 Santa Cruz Biot. Sc-1052 WB 1:2000 goat 
Hsp75/ Trap1 Santa Cruz Biot. Sc-135944 WB 1:2000 mouse 
Huntingtin mEM48  Millipore MAB5374 IHC 1:20-100 mouse 
Huntingtin 1HU-4C8 Millipore MAB2166 IHC 1:50-200 mouse 
IκBα Cell Signaling 9242 WB 1:1000 rabbit 
IκBα Cell Signaling 4814 WB 1:1000 mouse 
Myc (9E10) Santa Cruz Biot. Sc-40 IF 
WB 
1:500 
1:1000 
mouse 
Myc (A14) Santa Cruz Biot. Sc-789 IF 1:500 rabbit 
NF-κB p65 (C-20) Santa Cruz Biot. Sc-372 IF 
WB 
1:500 
1:1000 
rabbit, 
goat 
OPA1 BD Biosciences 612607 WB 1:1000 mouse 
PRK8 (Parkin) Santa Cruz Biot. Sc-32282 IF 
WB 
IHC 
1:1000 
1:2000 
1:10-20 
mouse 
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PARP Cell Signaling 9542S WB 1:1000 rabbit 
Phospho-IκBα Cell Signaling 9246 WB 1:1000 mouse 
Phospho-JNK (E11) Cell Signaling 4668 WB 1:1000 rabbit 
Phospho-c-Jun Cell Signaling 3270S IF 
WB 
1:1000 
1:1000 
rabbit 
P62 MBL PM045 IHC 1:10000 rabbit 
Sharpin Cell Signaling 4444S WB 1:1000 rabbit 
TIM44 BD Biosciences 612583 WB 1:4000 mouse 
TOM20 Santa Cruz Biot. Sc-11415 IF 
WB 
1:1000 
1:2000 
rabbit 
Tubulin Sigma Aldrich T5168 WB 1:5000 mouse 
Ubiquitin (P4D1) Santa Cruz Biot. 3270S WB 1:1000 mouse 
 
Secondary antibody Company Product nr. Applic. Dilution 
mouse-HRP Promega W4021 WB 1:10000 
rabbit-HRP Promega W4011 WB 1:10000 
goat-HRP Santa Cruz Biot. Sc-2020 WB 1:10000 
mouse-Alexa488 Invitrogen A-11029 IF 1:500 
mouse-Alexa555 Invitrogen A-21424 IF 1:500 
mouse-Alexa647 Invitrogen A-21236 IF 1:500 
rabbit-Alexa488 Invitrogen A-21245 IF 1:500 
rabbit-Alexa555 Invitrogen A-11034 IF 1:500 
rabbit-Alexa647 Invitrogen A-21429 IF 1:500 
 
b) Beads 
Beads Company 
Strep-Tactin Sepharose IBA 
 
c) Kits 
Kit Company 
ATP Bioluminescence Assay Kit HS II Roche 
Luciferase Assay System Promega 
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d) Chemicals and enzymes 
Reagents Company 
Amersham ECL Western Blotting Detection Reagent GE Healthcare 
BSA (Bovine serum albumine) New England Biolabs 
DAPI (4’,6’-Diamidino-2-phenylindole) Sigma Aldrich 
DNAse Sigma Aldrich 
Horse serum Sigma Aldrich 
Mowiol 4-88 Millipore 
PFA (Paraformaldehyde) Sigma Aldrich 
PI (complete protease inhibitor) Roche 
 
e) Equipment 
Product Company 
Cellulose acetate membrane, 0.2 µm GE Healthcare 
Centrifuge Multifuge 3 S-R Heraeus 
Centrifuge for Eppendorf tubes Eppendorf 
Freezer -20°C Elektrolux, Liebherr 
Freezer -80°C Heraeus, Kendro 
Fridge 4°C Elektrolux, Siemens 
Gel chamber Mini Trans-Blot Cell Bio-Rad 
Thermomixer comfort Eppendorf 
Luminometer LB96V Berthold Technologies 
Microscope Axio Imager A2 Zeiss 
Microscope Confocal LSM710 Zeiss 
Microscope cover glasses Marienfeld 
Microscope slide Thermo Scientific 
Milli-Q academic Millipore 
Nitrocellulose membrane, 0.2 µm Invitrogen 
pH-Meter WTW 
Power supply Bio-Rad 
PVDF membrane Millipore 
See Blue Plus2 (pre-stained protein standard) Invitrogen 
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Slot Blot PR 648 Hoefer Scientific 
Instruments 
Super RX (medical x-ray film) FUJIFILM 
Thermomixer compact Eppendorf 
Ultracentrifuge Optima MAX-XP Beckman Coulter 
Whatman paper Schleicher & Schüll 
 
f) Software 
Sotware Company 
Adobe Illustrator CS5 Adobe 
Adobe Photoshop CS5 Adobe 
Axiovision 4.7 Zeiss 
Microsoft Excel 2010 Microsoft 
Multi-Gauge V3.0 FUJIFILM 
WinGlow Berthold Technologies 
ZEN 2011 Zeiss 
 
 
6.2.2 Solutions and buffers 
a) General buffers 
PBS: 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 1.3 mM KCl, 135 mM NaCl pH 7.4 
 
b) Lysis buffers 
Detergent buffer:  0.5 - 1% Triton X-100 in PBS, protease inhibitor 
 
c) SDS gels and Western Blot buffers 
PBS-T:  PBS containing 0.1% Tween-20 
TBS:   25 mM Tris / HCl, 150 mM NaCl pH 7.2 
TBS-T:  TBS containing 0.1% Tween-20 
Laemmli sample buffer (4x): 
240 mM Tris / HCl pH 6.8, 4% SDS, 40 % glycerol, 2% bromophenol blue,  
4% β-mercaptoethanol 
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APS:      10% ammoniumperoxodisulfate in PBS 
Lower Tris Buffer for SDS-PAGE:  0.5 M Tris/HCl pH 6.8, 0.4% SDS 
Upper Tris Buffer for SDS-PAGE:  1.5M Tris/HCl pH 8.8, 0.4% SDS 
Running Buffer for SDS-PAGE:  25 mM Tris/HCl, 190 mM glycine, 0.1% SDS 
Blotting buffer:    25 mM Tris, 20 mM glycine 
Blocking buffer:    5% milk powder in TBS-T 
 
d) Immunofluorescence buffers 
Fixing solution:  3.7% Formaldehyde in PBS 
Permeabilization buffer: 0.1-0.2% Triton X-100 in PBS 
Blocking solution: 5% horse serum, 0.1% Tween20 in PBS (or 2.5% BSA in PBS) 
Mounting medium:  3.26 M glycerine, 2.72 M Mowiol 4-88, 0.12 M Tris pH8.5 in H2O 
 
e) Filter Trap buffers 
Lysis buffer:   1% Triton X-100, 15 mM MgCl2, 0.2 mg/ml DNAse in PBS 
SDS buffer:   2% SDS in 100 mM Tris pH 7 
 
f) Ubiquitination assay buffers 
HeBs buffer (2x):   50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4 
CaCl2 solution:  2.5 M CaCl2 
Denaturing lysis buffer: 1% SDS in PBS 
Dilution buffer:  1% Triton X-100 in PBS 
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